CA2953170A1 - Methods of treating or ameliorating migraine - Google Patents
Methods of treating or ameliorating migraine Download PDFInfo
- Publication number
- CA2953170A1 CA2953170A1 CA2953170A CA2953170A CA2953170A1 CA 2953170 A1 CA2953170 A1 CA 2953170A1 CA 2953170 A CA2953170 A CA 2953170A CA 2953170 A CA2953170 A CA 2953170A CA 2953170 A1 CA2953170 A1 CA 2953170A1
- Authority
- CA
- Canada
- Prior art keywords
- migraine
- patient
- compound
- administering
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000019695 Migraine disease Diseases 0.000 title claims abstract description 116
- 206010027599 migraine Diseases 0.000 title claims abstract description 114
- 238000000034 method Methods 0.000 title claims abstract description 75
- 230000007480 spreading Effects 0.000 claims abstract description 29
- 238000003892 spreading Methods 0.000 claims abstract description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 22
- 208000035475 disorder Diseases 0.000 claims abstract description 14
- 206010052784 Retinal migraine Diseases 0.000 claims abstract description 12
- 230000001667 episodic effect Effects 0.000 claims abstract description 12
- 208000006561 Cluster Headache Diseases 0.000 claims abstract description 11
- 206010049714 Abdominal migraine Diseases 0.000 claims abstract description 10
- 208000018912 cluster headache syndrome Diseases 0.000 claims abstract description 10
- 230000000737 periodic effect Effects 0.000 claims abstract description 10
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 10
- 230000001054 cortical effect Effects 0.000 claims abstract description 8
- 208000005056 Ophthalmoplegic Migraine Diseases 0.000 claims abstract description 7
- 230000007774 longterm Effects 0.000 claims abstract description 5
- 208000030886 Traumatic Brain injury Diseases 0.000 claims abstract description 4
- 230000009529 traumatic brain injury Effects 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 53
- 208000000060 Migraine with aura Diseases 0.000 claims description 28
- 206010019233 Headaches Diseases 0.000 claims description 23
- 231100000869 headache Toxicity 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 13
- 206010052787 migraine without aura Diseases 0.000 claims description 9
- 230000001430 anti-depressive effect Effects 0.000 claims description 8
- 239000000935 antidepressant agent Substances 0.000 claims description 8
- 229940005513 antidepressants Drugs 0.000 claims description 8
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 8
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 8
- 239000000556 agonist Substances 0.000 claims description 7
- 208000004454 Hyperalgesia Diseases 0.000 claims description 5
- 206010053552 allodynia Diseases 0.000 claims description 5
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 5
- 239000001961 anticonvulsive agent Substances 0.000 claims description 5
- 230000003203 everyday effect Effects 0.000 claims description 5
- 230000003556 anti-epileptic effect Effects 0.000 claims description 4
- 238000011260 co-administration Methods 0.000 claims description 4
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims description 4
- 229940076279 serotonin Drugs 0.000 claims description 4
- 230000001773 anti-convulsant effect Effects 0.000 claims description 2
- 229960003965 antiepileptics Drugs 0.000 claims 2
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 36
- 206010015037 epilepsy Diseases 0.000 abstract description 28
- 201000010099 disease Diseases 0.000 abstract description 8
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 abstract description 7
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 abstract description 7
- 239000004031 partial agonist Substances 0.000 abstract description 7
- GIBQQARAXHVEGD-BSOLPCOYSA-N rapastinel Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)N[C@@H]([C@@H](C)O)C(N)=O)CCC1 GIBQQARAXHVEGD-BSOLPCOYSA-N 0.000 description 75
- 239000000203 mixture Substances 0.000 description 55
- 241000700159 Rattus Species 0.000 description 31
- 238000011282 treatment Methods 0.000 description 30
- 230000000694 effects Effects 0.000 description 28
- -1 but not limited to Chemical compound 0.000 description 24
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 22
- 230000000977 initiatory effect Effects 0.000 description 19
- 238000012360 testing method Methods 0.000 description 18
- 229940011871 estrogen Drugs 0.000 description 16
- 239000000262 estrogen Substances 0.000 description 16
- 208000024891 symptom Diseases 0.000 description 16
- 239000003814 drug Substances 0.000 description 15
- 238000009472 formulation Methods 0.000 description 15
- 210000004556 brain Anatomy 0.000 description 14
- 210000003520 dendritic spine Anatomy 0.000 description 14
- 230000000971 hippocampal effect Effects 0.000 description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- 208000002193 Pain Diseases 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 230000036407 pain Effects 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 230000000763 evoking effect Effects 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 108010024875 GLYX-13 peptide Proteins 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 229950000471 rapastinel Drugs 0.000 description 9
- 238000011084 recovery Methods 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 230000028161 membrane depolarization Effects 0.000 description 8
- 210000001176 projection neuron Anatomy 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 238000000540 analysis of variance Methods 0.000 description 7
- 210000001320 hippocampus Anatomy 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 230000002996 emotional effect Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 206010003591 Ataxia Diseases 0.000 description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 208000012886 Vertigo Diseases 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 210000003128 head Anatomy 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000027928 long-term synaptic potentiation Effects 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010027603 Migraine headaches Diseases 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 210000003050 axon Anatomy 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000036279 refractory period Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000000133 brain stem Anatomy 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 210000001787 dendrite Anatomy 0.000 description 3
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 3
- 229960004193 dextropropoxyphene Drugs 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 210000001723 extracellular space Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 208000017420 migraine with brainstem aura Diseases 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000010149 post-hoc-test Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000009987 spinning Methods 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000000946 synaptic effect Effects 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 231100001274 therapeutic index Toxicity 0.000 description 3
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 2
- MHNSPTUQQIYJOT-CULRIWENSA-N (3z)-3-(6h-benzo[c][1]benzoxepin-11-ylidene)-n,n-dimethylpropan-1-amine;hydrochloride Chemical compound Cl.C1OC2=CC=CC=C2C(=C/CCN(C)C)\C2=CC=CC=C21 MHNSPTUQQIYJOT-CULRIWENSA-N 0.000 description 2
- UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 239000012110 Alexa Fluor 594 Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 102000001267 GSK3 Human genes 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- 102000018899 Glutamate Receptors Human genes 0.000 description 2
- 108010027915 Glutamate Receptors Proteins 0.000 description 2
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001024304 Mino Species 0.000 description 2
- 206010027940 Mood altered Diseases 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- 206010060860 Neurological symptom Diseases 0.000 description 2
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical group C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 206010034972 Photosensitivity reaction Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010039677 Scintillating scotoma Diseases 0.000 description 2
- 206010039729 Scotoma Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000004830 Super Glue Substances 0.000 description 2
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 2
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 2
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 206010071669 Typical aura without headache Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 239000005388 borosilicate glass Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- WAZQAZKAZLXFMK-UHFFFAOYSA-N deracoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 WAZQAZKAZLXFMK-UHFFFAOYSA-N 0.000 description 2
- 229960003314 deracoxib Drugs 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- FGBJXOREULPLGL-UHFFFAOYSA-N ethyl cyanoacrylate Chemical compound CCOC(=O)C(=C)C#N FGBJXOREULPLGL-UHFFFAOYSA-N 0.000 description 2
- 229960004945 etoricoxib Drugs 0.000 description 2
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 2
- 208000035238 familial hemiplegic 1 migraine Diseases 0.000 description 2
- 206010067039 familial hemiplegic migraine Diseases 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 210000001652 frontal lobe Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000001307 helium Substances 0.000 description 2
- 229910052734 helium Inorganic materials 0.000 description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 2
- 210000001879 hippocampal ca1 region Anatomy 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229960001797 methadone Drugs 0.000 description 2
- 229960000600 milnacipran Drugs 0.000 description 2
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 208000018731 motor weakness Diseases 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 208000035824 paresthesia Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 208000007578 phototoxic dermatitis Diseases 0.000 description 2
- 231100000018 phototoxicity Toxicity 0.000 description 2
- 229960002702 piroxicam Drugs 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 229920006267 polyester film Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001902 propagating effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229960000371 rofecoxib Drugs 0.000 description 2
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 2
- 238000004621 scanning probe microscopy Methods 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical compound OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 230000035943 smell Effects 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 208000006122 sporadic hemiplegic migraine Diseases 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229960000894 sulindac Drugs 0.000 description 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 229960004492 suprofen Drugs 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 229960001017 tolmetin Drugs 0.000 description 2
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229960004394 topiramate Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 229960003991 trazodone Drugs 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- ZISSAWUMDACLOM-UHFFFAOYSA-N triptane Chemical compound CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 description 2
- 238000007492 two-way ANOVA Methods 0.000 description 2
- 229960002004 valdecoxib Drugs 0.000 description 2
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- KTGRHKOEFSJQNS-BDQAORGHSA-N (1s)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;oxalic acid Chemical compound OC(=O)C(O)=O.C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 KTGRHKOEFSJQNS-BDQAORGHSA-N 0.000 description 1
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 description 1
- AJQRDRIPQOAJCM-BWOKQULHSA-N (2r,5r)-2-[(1s,2r)-2-amino-2-carboxy-1-hydroxyethyl]-5-[(2s)-2-carboxy-2-[(3,5-dichloro-4-hydroxybenzoyl)amino]ethyl]pyrrolidine-2-carboxylic acid Chemical compound N1[C@]([C@@H](O)[C@@H](N)C(O)=O)(C(O)=O)CC[C@@H]1C[C@@H](C(O)=O)NC(=O)C1=CC(Cl)=C(O)C(Cl)=C1 AJQRDRIPQOAJCM-BWOKQULHSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- GUHPRPJDBZHYCJ-SECBINFHSA-N (2s)-2-(5-benzoylthiophen-2-yl)propanoic acid Chemical compound S1C([C@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-SECBINFHSA-N 0.000 description 1
- KYZWKYWGQFCRGN-OASOTCBPSA-N (2s)-2-aminopentanedioic acid;(2r)-2-(methylamino)butanedioic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O.OC(=O)[C@@H](N)CCC(O)=O KYZWKYWGQFCRGN-OASOTCBPSA-N 0.000 description 1
- PZUOEYPTQJILHP-GBXIJSLDSA-N (2s,3r)-2-amino-3-hydroxybutanamide Chemical compound C[C@@H](O)[C@H](N)C(N)=O PZUOEYPTQJILHP-GBXIJSLDSA-N 0.000 description 1
- KRZJRNZICWNMOA-GXSJLCMTSA-N (3s,4r)-4,8-dihydroxy-3-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1=CC=C2[C@@H](O)[C@@H](OC)CC(=O)C2=C1O KRZJRNZICWNMOA-GXSJLCMTSA-N 0.000 description 1
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 1
- DQNMZSIJHFEYTM-LEWJYISDSA-N (4s,5r)-3-[3-(azepan-1-yl)propyl]-4-(2-methylpropyl)-5-phenyl-1,3-oxazolidin-2-one Chemical compound O([C@@H]([C@@H]1CC(C)C)C=2C=CC=CC=2)C(=O)N1CCCN1CCCCCC1 DQNMZSIJHFEYTM-LEWJYISDSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- KGSABFQIAANNPS-UHFFFAOYSA-N 1-(3-chlorophenyl)-3-(dimethylamino)-1-phenylpropan-2-ol Chemical compound C=1C=CC(Cl)=CC=1C(C(O)CN(C)C)C1=CC=CC=C1 KGSABFQIAANNPS-UHFFFAOYSA-N 0.000 description 1
- WSEQXVZVJXJVFP-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- STDYWHYUOSSCBO-UHFFFAOYSA-N 2,3-dimethyl-4-phenyl-4,5-dihydro-1,3-benzodiazepine Chemical compound C1C2=CC=CC=C2N=C(C)N(C)C1C1=CC=CC=C1 STDYWHYUOSSCBO-UHFFFAOYSA-N 0.000 description 1
- NUMXHEUHHRTBQT-AATRIKPKSA-N 2,4-dimethoxy-1-[(e)-2-nitroethenyl]benzene Chemical compound COC1=CC=C(\C=C\[N+]([O-])=O)C(OC)=C1 NUMXHEUHHRTBQT-AATRIKPKSA-N 0.000 description 1
- JYWLVKREVMTEJA-ZEQRLZLVSA-N 2-[4-[(2s)-2-acetamido-3-[[5-[[(1s)-1-carboxy-3-methylsulfanylpropyl]amino]-5-oxopentyl]amino]-3-oxopropyl]-2-ethyl-n-oxaloanilino]benzoic acid Chemical compound CCC1=CC(C[C@H](NC(C)=O)C(=O)NCCCCC(=O)N[C@@H](CCSC)C(O)=O)=CC=C1N(C(=O)C(O)=O)C1=CC=CC=C1C(O)=O JYWLVKREVMTEJA-ZEQRLZLVSA-N 0.000 description 1
- WKAVKKUXZAWHDM-UHFFFAOYSA-N 2-acetamidopentanedioic acid;2-(dimethylamino)ethanol Chemical compound CN(C)CCO.CC(=O)NC(C(O)=O)CCC(O)=O WKAVKKUXZAWHDM-UHFFFAOYSA-N 0.000 description 1
- YSGASDXSLKIKOD-UHFFFAOYSA-N 2-amino-N-(1,2-diphenylpropan-2-yl)acetamide Chemical compound C=1C=CC=CC=1C(C)(NC(=O)CN)CC1=CC=CC=C1 YSGASDXSLKIKOD-UHFFFAOYSA-N 0.000 description 1
- AJYAGCQANRNGJY-UHFFFAOYSA-N 2-quinoxalin-5-ylacetamide Chemical compound C1=CN=C2C(CC(=O)N)=CC=CC2=N1 AJYAGCQANRNGJY-UHFFFAOYSA-N 0.000 description 1
- MVVJINIUPYKZHR-UHFFFAOYSA-N 3-[[4-[5-(methoxymethyl)-2-oxo-1,3-oxazolidin-3-yl]phenoxy]methyl]benzonitrile Chemical compound O=C1OC(COC)CN1C(C=C1)=CC=C1OCC1=CC=CC(C#N)=C1 MVVJINIUPYKZHR-UHFFFAOYSA-N 0.000 description 1
- NOIIUHRQUVNIDD-UHFFFAOYSA-N 3-[[oxo(pyridin-4-yl)methyl]hydrazo]-N-(phenylmethyl)propanamide Chemical compound C=1C=CC=CC=1CNC(=O)CCNNC(=O)C1=CC=NC=C1 NOIIUHRQUVNIDD-UHFFFAOYSA-N 0.000 description 1
- NDPOGPAZKKPOPV-UHFFFAOYSA-N 4-(4-ethylphenyl)piperidine Chemical compound C1=CC(CC)=CC=C1C1CCNCC1 NDPOGPAZKKPOPV-UHFFFAOYSA-N 0.000 description 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 1
- MXUNKHLAEDCYJL-UHFFFAOYSA-N 5-(hydroxymethyl)-3-(3-methylphenyl)-1,3-oxazolidin-2-one Chemical compound CC1=CC=CC(N2C(OC(CO)C2)=O)=C1 MXUNKHLAEDCYJL-UHFFFAOYSA-N 0.000 description 1
- QPGGEKPRGVJKQB-UHFFFAOYSA-N 5-[2-(dimethylamino)ethyl]-11-methyl-6-benzo[b][1,4]benzodiazepinone Chemical compound O=C1N(CCN(C)C)C2=CC=CC=C2N(C)C2=CC=CC=C21 QPGGEKPRGVJKQB-UHFFFAOYSA-N 0.000 description 1
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- JICJBGPOMZQUBB-UHFFFAOYSA-N 7-[(3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid Chemical compound O=S1(=O)N(C)C2=CC=CC=C2C(NCCCCCCC(O)=O)C2=CC=C(Cl)C=C21 JICJBGPOMZQUBB-UHFFFAOYSA-N 0.000 description 1
- KSCOHHUVHWAXLK-UHFFFAOYSA-N 7-chloro-4-sulfanylidene-1h-quinoline-2-carboxylic acid Chemical compound C1=C(Cl)C=C2NC(C(=O)O)=CC(=S)C2=C1 KSCOHHUVHWAXLK-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- KFYRPLNVJVHZGT-UHFFFAOYSA-N Amitriptyline hydrochloride Chemical compound Cl.C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KFYRPLNVJVHZGT-UHFFFAOYSA-N 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 206010003791 Aura Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 206010050258 Basilar migraine Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 102100024881 C3 and PZP-like alpha-2-macroglobulin domain-containing protein 8 Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010051290 Central nervous system lesion Diseases 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 108010065372 Dynorphins Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 208000010541 Familial or sporadic hemiplegic migraine Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- ZCDHNOUTBZTCLP-UHFFFAOYSA-N Fluorofelbamate Chemical compound NC(=O)OCC(F)(COC(N)=O)C1=CC=CC=C1 ZCDHNOUTBZTCLP-UHFFFAOYSA-N 0.000 description 1
- LFMYNZPAVPMEGP-PIDGMYBPSA-N Fluvoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 LFMYNZPAVPMEGP-PIDGMYBPSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 208000027109 Headache disease Diseases 0.000 description 1
- 206010019452 Hemianopia Diseases 0.000 description 1
- 208000007460 Hemianopsia Diseases 0.000 description 1
- 206010019476 Hemiplegic migraine Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000629937 Homo sapiens Translocon-associated protein subunit alpha Proteins 0.000 description 1
- MADRVGBADLFHMO-UHFFFAOYSA-N Indeloxazine Chemical compound C=1C=CC=2C=CCC=2C=1OCC1CNCCO1 MADRVGBADLFHMO-UHFFFAOYSA-N 0.000 description 1
- 102000006541 Ionotropic Glutamate Receptors Human genes 0.000 description 1
- 108010008812 Ionotropic Glutamate Receptors Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
- ALFGKMXHOUSVAD-UHFFFAOYSA-N Ketobemidone Chemical compound C=1C=CC(O)=CC=1C1(C(=O)CC)CCN(C)CC1 ALFGKMXHOUSVAD-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- IWVRVEIKCBFZNF-UHFFFAOYSA-N LSM-1636 Chemical compound C1CNC2CCCC3=C2N1C1=CC=C(C)C=C13 IWVRVEIKCBFZNF-UHFFFAOYSA-N 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229920005479 Lucite® Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 description 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- RSHMQGIMHQPMEB-IXOXFDKPSA-N Montirelin Chemical compound N1C(=O)[C@@H](C)SC[C@H]1C(=O)N[C@H](C(=O)N1[C@@H](CCC1)C(N)=O)CC1=CN=CN1 RSHMQGIMHQPMEB-IXOXFDKPSA-N 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 1
- JUUFBMODXQKSTD-UHFFFAOYSA-N N-[2-amino-6-[(4-fluorophenyl)methylamino]-3-pyridinyl]carbamic acid ethyl ester Chemical compound N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 JUUFBMODXQKSTD-UHFFFAOYSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- RGPDEAGGEXEMMM-UHFFFAOYSA-N Nefopam Chemical compound C12=CC=CC=C2CN(C)CCOC1C1=CC=CC=C1 RGPDEAGGEXEMMM-UHFFFAOYSA-N 0.000 description 1
- 102400001103 Neurotensin Human genes 0.000 description 1
- 101800001814 Neurotensin Proteins 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 241000183024 Populus tremula Species 0.000 description 1
- 102100024622 Proenkephalin-B Human genes 0.000 description 1
- ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 241001522306 Serinus serinus Species 0.000 description 1
- 206010040108 Serotonin syndrome Diseases 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 102400000096 Substance P Human genes 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- 206010042464 Suicide attempt Diseases 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- UNZIDPIPYUMVPA-UHFFFAOYSA-M Sulpyrine Chemical compound O.[Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 UNZIDPIPYUMVPA-UHFFFAOYSA-M 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- 206010043431 Thinking abnormal Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical group [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- RUJBDQSFYCKFAA-UHFFFAOYSA-N Tofisopam Chemical compound N=1N=C(C)C(CC)C2=CC(OC)=C(OC)C=C2C=1C1=CC=C(OC)C(OC)=C1 RUJBDQSFYCKFAA-UHFFFAOYSA-N 0.000 description 1
- 102100026231 Translocon-associated protein subunit alpha Human genes 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- BKPRVQDIOGQWTG-ICOOEGOYSA-N [(1s,2r)-2-phenylcyclopropyl]azanium;[(1r,2s)-2-phenylcyclopropyl]azanium;sulfate Chemical compound [O-]S([O-])(=O)=O.[NH3+][C@H]1C[C@@H]1C1=CC=CC=C1.[NH3+][C@@H]1C[C@H]1C1=CC=CC=C1 BKPRVQDIOGQWTG-ICOOEGOYSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- HLAFSNJRKZLMPT-UHFFFAOYSA-N [2-[2-(aminomethyl)phenyl]sulfanylphenyl]methanol Chemical compound NCC1=CC=CC=C1SC1=CC=CC=C1CO HLAFSNJRKZLMPT-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 229960004892 acemetacin Drugs 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960003148 adinazolam Drugs 0.000 description 1
- GJSLOMWRLALDCT-UHFFFAOYSA-N adinazolam Chemical compound C12=CC(Cl)=CC=C2N2C(CN(C)C)=NN=C2CN=C1C1=CC=CC=C1 GJSLOMWRLALDCT-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960001391 alfentanil Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960000959 amineptine Drugs 0.000 description 1
- VDPUXONTAVMIKZ-UHFFFAOYSA-N amineptine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2C([NH2+]CCCCCCC(=O)O)C2=CC=CC=C21 VDPUXONTAVMIKZ-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229940042749 amitriptyline / chlordiazepoxide Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229940025141 anafranil Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- BFNCJMURTMZBTE-UHFFFAOYSA-N aptiganel Chemical compound CCC1=CC=CC(N(C)C(N)=NC=2C3=CC=CC=C3C=CC=2)=C1 BFNCJMURTMZBTE-UHFFFAOYSA-N 0.000 description 1
- 229950001180 aptiganel Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229960002430 atomoxetine Drugs 0.000 description 1
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 1
- 210000001841 basilar artery Anatomy 0.000 description 1
- KRNDIPHOJLIHRI-UHFFFAOYSA-N bazinaprine Chemical compound N#CC1=CC(C=2C=CC=CC=2)=NN=C1NCCN1CCOCC1 KRNDIPHOJLIHRI-UHFFFAOYSA-N 0.000 description 1
- 229950005683 bazinaprine Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- SXYFFMXPDDGOEK-UHFFFAOYSA-N binedaline Chemical compound C12=CC=CC=C2N(N(C)CCN(C)C)C=C1C1=CC=CC=C1 SXYFFMXPDDGOEK-UHFFFAOYSA-N 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229950009454 bipenamol Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- WZXHSWVDAYOFPE-UHFFFAOYSA-N brofaromine Chemical compound C=1C2=CC(OC)=CC(Br)=C2OC=1C1CCNCC1 WZXHSWVDAYOFPE-UHFFFAOYSA-N 0.000 description 1
- 229950004068 brofaromine Drugs 0.000 description 1
- QIHLUZAFSSMXHQ-UHFFFAOYSA-N budipine Chemical compound C1CN(C(C)(C)C)CCC1(C=1C=CC=CC=1)C1=CC=CC=C1 QIHLUZAFSSMXHQ-UHFFFAOYSA-N 0.000 description 1
- 229960002452 budipine Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 229940047493 celexa Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- YCWROMXNZZIJDQ-UHFFFAOYSA-N chembl174697 Chemical compound C1=2C(C)=NN(C)C=2NCCN=C1C1=CC=CC(Cl)=C1 YCWROMXNZZIJDQ-UHFFFAOYSA-N 0.000 description 1
- ZGLIFVFRIOKQLE-LVZFUZTISA-N chembl2104573 Chemical compound C=1C(Cl)=CC=C(O)C=1C(=N/CCCC)/C1=CC=CC=C1Cl ZGLIFVFRIOKQLE-LVZFUZTISA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229950001408 cianopramine Drugs 0.000 description 1
- LQXYCDLHSKICDY-UHFFFAOYSA-N cianopramine Chemical compound C1CC2=CC=C(C#N)C=C2N(CCCN(C)C)C2=CC=CC=C21 LQXYCDLHSKICDY-UHFFFAOYSA-N 0.000 description 1
- 229950001660 cimoxatone Drugs 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229950009328 clemeprol Drugs 0.000 description 1
- 229950002663 clovoxamine Drugs 0.000 description 1
- XXPVSQRPGBUFKM-SAPNQHFASA-N clovoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(Cl)C=C1 XXPVSQRPGBUFKM-SAPNQHFASA-N 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- HTBKFGWATIYCSF-QGXIKSNHSA-N conantokin g Chemical compound NC(=O)C[C@@H](C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C(O)=O)C(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C(O)=O)C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C(O)=O)C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C(O)=O)C(O)=O)NC(=O)[C@H](CC(C(O)=O)C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CN HTBKFGWATIYCSF-QGXIKSNHSA-N 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 229940029644 cymbalta Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 229950005551 dazepinil Drugs 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- MUGNLPWYHGOJEG-UHFFFAOYSA-N delucemine Chemical compound C=1C=CC(F)=CC=1C(CCNC)C1=CC=CC(F)=C1 MUGNLPWYHGOJEG-UHFFFAOYSA-N 0.000 description 1
- 229950006926 delucemine Drugs 0.000 description 1
- 208000017004 dementia pugilistica Diseases 0.000 description 1
- 229950010189 demexiptiline Drugs 0.000 description 1
- SEDQWOMFMIJKCU-UHFFFAOYSA-N demexiptiline Chemical compound C1=CC2=CC=CC=C2C(=NOCCNC)C2=CC=CC=C21 SEDQWOMFMIJKCU-UHFFFAOYSA-N 0.000 description 1
- SSQJFGMEZBFMNV-PMACEKPBSA-N dexanabinol Chemical compound C1C(CO)=CC[C@@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@H]21 SSQJFGMEZBFMNV-PMACEKPBSA-N 0.000 description 1
- WDEFBBTXULIOBB-WBVHZDCISA-N dextilidine Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)OCC)CCC=C[C@H]1N(C)C WDEFBBTXULIOBB-WBVHZDCISA-N 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- INUNXTSAACVKJS-OAQYLSRUSA-N dextromoramide Chemical compound C([C@@H](C)C(C(=O)N1CCCC1)(C=1C=CC=CC=1)C=1C=CC=CC=1)N1CCOCC1 INUNXTSAACVKJS-OAQYLSRUSA-N 0.000 description 1
- 229960003701 dextromoramide Drugs 0.000 description 1
- 229960003461 dezocine Drugs 0.000 description 1
- VTMVHDZWSFQSQP-VBNZEHGJSA-N dezocine Chemical compound C1CCCC[C@H]2CC3=CC=C(O)C=C3[C@]1(C)[C@H]2N VTMVHDZWSFQSQP-VBNZEHGJSA-N 0.000 description 1
- 229960003075 dibenzepin Drugs 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000001152 differential interference contrast microscopy Methods 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 1
- 229960000920 dihydrocodeine Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
- 229960004192 diphenoxylate Drugs 0.000 description 1
- 229940120889 dipyrone Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960001393 dosulepin Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229940098766 effexor Drugs 0.000 description 1
- 229940011681 elavil Drugs 0.000 description 1
- 229960002472 eletriptan Drugs 0.000 description 1
- OTLDLQZJRFYOJR-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC1=CN=C2[C]1C=C(CCS(=O)(=O)C=1C=CC=CC=1)C=C2 OTLDLQZJRFYOJR-LJQANCHMSA-N 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 229950004233 enefexine Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229960002336 estazolam Drugs 0.000 description 1
- CDCHDCWJMGXXRH-UHFFFAOYSA-N estazolam Chemical compound C=1C(Cl)=CC=C(N2C=NN=C2CN=2)C=1C=2C1=CC=CC=C1 CDCHDCWJMGXXRH-UHFFFAOYSA-N 0.000 description 1
- 229960000514 ethenzamide Drugs 0.000 description 1
- SBNKFTQSBPKMBZ-UHFFFAOYSA-N ethenzamide Chemical compound CCOC1=CC=CC=C1C(N)=O SBNKFTQSBPKMBZ-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 229960005437 etoperidone Drugs 0.000 description 1
- IZBNNCFOBMGTQX-UHFFFAOYSA-N etoperidone Chemical compound O=C1N(CC)C(CC)=NN1CCCN1CCN(C=2C=C(Cl)C=CC=2)CC1 IZBNNCFOBMGTQX-UHFFFAOYSA-N 0.000 description 1
- CAHCBJPUTCKATP-FAWZKKEFSA-N etorphine Chemical compound O([C@H]1[C@@]2(OC)C=C[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O CAHCBJPUTCKATP-FAWZKKEFSA-N 0.000 description 1
- 229950004155 etorphine Drugs 0.000 description 1
- 230000021824 exploration behavior Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 230000000193 eyeblink Effects 0.000 description 1
- PCOBBVZJEWWZFR-UHFFFAOYSA-N ezogabine Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 PCOBBVZJEWWZFR-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229960003472 felbamate Drugs 0.000 description 1
- WKGXYQFOCVYPAC-UHFFFAOYSA-N felbamate Chemical compound NC(=O)OCC(COC(N)=O)C1=CC=CC=C1 WKGXYQFOCVYPAC-UHFFFAOYSA-N 0.000 description 1
- 229950004395 fengabine Drugs 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- NELSQLPTEWCHQW-UHFFFAOYSA-N fezolamine Chemical compound N=1N(CCCN(C)C)C=C(C=2C=CC=CC=2)C=1C1=CC=CC=C1 NELSQLPTEWCHQW-UHFFFAOYSA-N 0.000 description 1
- 229950000761 fezolamine Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 101150083480 fliS gene Proteins 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940085879 fluor-op Drugs 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 1
- 229960003667 flupirtine Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000007946 glucose deprivation Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- SADQVAVFGNTEOD-UHFFFAOYSA-N indalpine Chemical compound C=1NC2=CC=CC=C2C=1CCC1CCNCC1 SADQVAVFGNTEOD-UHFFFAOYSA-N 0.000 description 1
- 229950002473 indalpine Drugs 0.000 description 1
- 229960004333 indeloxazine Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 1
- 230000001057 ionotropic effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229950010499 ipenoxazone Drugs 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 description 1
- 229950002252 isoxicam Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960000194 kebuzone Drugs 0.000 description 1
- LGYTZKPVOAIUKX-UHFFFAOYSA-N kebuzone Chemical compound O=C1C(CCC(=O)C)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 LGYTZKPVOAIUKX-UHFFFAOYSA-N 0.000 description 1
- 229960003029 ketobemidone Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 229960001848 lamotrigine Drugs 0.000 description 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
- FWUQWDCOOWEXRY-ZDUSSCGKSA-N lanicemine Chemical compound C([C@H](N)C=1C=CC=CC=1)C1=CC=CC=N1 FWUQWDCOOWEXRY-ZDUSSCGKSA-N 0.000 description 1
- 229950003165 lanicemine Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- USSIQXCVUWKGNF-QGZVFWFLSA-N levomethadone Chemical compound C=1C=CC=CC=1C(C[C@@H](C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-QGZVFWFLSA-N 0.000 description 1
- 229960002710 levomethadone Drugs 0.000 description 1
- 229960003406 levorphanol Drugs 0.000 description 1
- 229940054157 lexapro Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- MJJDYOLPMGIWND-UHFFFAOYSA-N litoxetine Chemical compound C=1C=C2C=CC=CC2=CC=1COC1CCNCC1 MJJDYOLPMGIWND-UHFFFAOYSA-N 0.000 description 1
- 229950004138 litoxetine Drugs 0.000 description 1
- XVUQHFRQHBLHQD-UHFFFAOYSA-N lonazolac Chemical compound OC(=O)CC1=CN(C=2C=CC=CC=2)N=C1C1=CC=C(Cl)C=C1 XVUQHFRQHBLHQD-UHFFFAOYSA-N 0.000 description 1
- 229960003768 lonazolac Drugs 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229960002202 lornoxicam Drugs 0.000 description 1
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229940009622 luvox Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 229940110127 marplan Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960003123 medifoxamine Drugs 0.000 description 1
- QNMGHBMGNRQPNL-UHFFFAOYSA-N medifoxamine Chemical compound C=1C=CC=CC=1OC(CN(C)C)OC1=CC=CC=C1 QNMGHBMGNRQPNL-UHFFFAOYSA-N 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- JLICHNCFTLFZJN-HNNXBMFYSA-N meptazinol Chemical compound C=1C=CC(O)=CC=1[C@@]1(CC)CCCCN(C)C1 JLICHNCFTLFZJN-HNNXBMFYSA-N 0.000 description 1
- 229960000365 meptazinol Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229950006180 metapramine Drugs 0.000 description 1
- YXVZOBVWVRFPTE-UHFFFAOYSA-N metapramine Chemical compound CNC1CC2=CC=CC=C2N(C)C2=CC=CC=C12 YXVZOBVWVRFPTE-UHFFFAOYSA-N 0.000 description 1
- 229950006787 metralindole Drugs 0.000 description 1
- GVXBHSBKKJRBMS-UHFFFAOYSA-N metralindole Chemical compound C1CN(C)C2=NCCC3=C2N1C1=CC=C(OC)C=C13 GVXBHSBKKJRBMS-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- VZXMZMJSGLFKQI-ABVWVHJUSA-N midafotel Chemical compound OC(=O)[C@H]1CN(C\C=C\P(O)(O)=O)CCN1 VZXMZMJSGLFKQI-ABVWVHJUSA-N 0.000 description 1
- 229950004300 midafotel Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229960004758 minaprine Drugs 0.000 description 1
- LDMWSLGGVTVJPG-UHFFFAOYSA-N minaprine Chemical compound CC1=CC(C=2C=CC=CC=2)=NN=C1NCCN1CCOCC1 LDMWSLGGVTVJPG-UHFFFAOYSA-N 0.000 description 1
- 229960001785 mirtazapine Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960005285 mofebutazone Drugs 0.000 description 1
- REOJLIXKJWXUGB-UHFFFAOYSA-N mofebutazone Chemical compound O=C1C(CCCC)C(=O)NN1C1=CC=CC=C1 REOJLIXKJWXUGB-UHFFFAOYSA-N 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 229950004759 montirelin Drugs 0.000 description 1
- 108700023195 montirelin Proteins 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000001095 motoneuron effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- XZOCIZHAHWDUPU-QWRGUYRKSA-N n-[(2s)-1-[(2s)-2-carbamoylpyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]-2,4-dioxo-1h-pyrimidine-6-carboxamide Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)C=1NC(=O)NC(=O)C=1)CC1=CN=CN1 XZOCIZHAHWDUPU-QWRGUYRKSA-N 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 description 1
- 229960005254 naratriptan Drugs 0.000 description 1
- 229940087524 nardil Drugs 0.000 description 1
- 229960000751 nefopam Drugs 0.000 description 1
- 210000000478 neocortex Anatomy 0.000 description 1
- OGZQTTHDGQBLBT-UHFFFAOYSA-N neramexane Chemical compound CC1(C)CC(C)(C)CC(C)(N)C1 OGZQTTHDGQBLBT-UHFFFAOYSA-N 0.000 description 1
- 229950004543 neramexane Drugs 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 description 1
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 1
- 229960003057 nialamide Drugs 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 229940087480 norpramin Drugs 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 229950005403 orotirelin Drugs 0.000 description 1
- 108700031265 orotirelin Proteins 0.000 description 1
- 229960003941 orphenadrine Drugs 0.000 description 1
- QVYRGXJJSLMXQH-UHFFFAOYSA-N orphenadrine Chemical compound C=1C=CC=C(C)C=1C(OCCN(C)C)C1=CC=CC=C1 QVYRGXJJSLMXQH-UHFFFAOYSA-N 0.000 description 1
- 229960002019 oxaflozane Drugs 0.000 description 1
- FVYUQFQCEOZYHZ-UHFFFAOYSA-N oxaflozane Chemical compound C1N(C(C)C)CCOC1C1=CC=CC(C(F)(F)F)=C1 FVYUQFQCEOZYHZ-UHFFFAOYSA-N 0.000 description 1
- 229960001816 oxcarbazepine Drugs 0.000 description 1
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- CNDQSXOVEQXJOE-UHFFFAOYSA-N oxyphenbutazone hydrate Chemical compound O.O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 CNDQSXOVEQXJOE-UHFFFAOYSA-N 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 229940055692 pamelor Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229960004662 parecoxib Drugs 0.000 description 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
- 229940087824 parnate Drugs 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- CMCWWLVWPDLCRM-UHFFFAOYSA-N phenidone Chemical compound N1C(=O)CCN1C1=CC=CC=C1 CMCWWLVWPDLCRM-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- IHEHEFLXQFOQJO-UHFFFAOYSA-N piritramide Chemical compound C1CC(C(=O)N)(N2CCCCC2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 IHEHEFLXQFOQJO-UHFFFAOYSA-N 0.000 description 1
- 229960001286 piritramide Drugs 0.000 description 1
- 229950002220 pirlindole Drugs 0.000 description 1
- FIADGNVRKBPQEU-UHFFFAOYSA-N pizotifen Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CCC2=C1C=CS2 FIADGNVRKBPQEU-UHFFFAOYSA-N 0.000 description 1
- 229960004572 pizotifen Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000002064 post-exposure prophylaxis Effects 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 210000002442 prefrontal cortex Anatomy 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960003192 propacetamol Drugs 0.000 description 1
- QTGAJCQTLIRCFL-UHFFFAOYSA-N propacetamol Chemical compound CCN(CC)CC(=O)OC1=CC=C(NC(C)=O)C=C1 QTGAJCQTLIRCFL-UHFFFAOYSA-N 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960002189 propyphenazone Drugs 0.000 description 1
- PXWLVJLKJGVOKE-UHFFFAOYSA-N propyphenazone Chemical compound O=C1C(C(C)C)=C(C)N(C)N1C1=CC=CC=C1 PXWLVJLKJGVOKE-UHFFFAOYSA-N 0.000 description 1
- OGQDIIKRQRZXJH-UHFFFAOYSA-N protriptyline hydrochloride Chemical compound [Cl-].C1=CC2=CC=CC=C2C(CCC[NH2+]C)C2=CC=CC=C21 OGQDIIKRQRZXJH-UHFFFAOYSA-N 0.000 description 1
- 229940035613 prozac Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229950000659 remacemide Drugs 0.000 description 1
- 229940023942 remeron Drugs 0.000 description 1
- 229960003394 remifentanil Drugs 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 239000000837 restrainer Substances 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 229960003312 retigabine Drugs 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- JUQLTPCYUFPYKE-UHFFFAOYSA-N ritanserin Chemical compound CC=1N=C2SC=CN2C(=O)C=1CCN(CC1)CCC1=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 JUQLTPCYUFPYKE-UHFFFAOYSA-N 0.000 description 1
- 229950009626 ritanserin Drugs 0.000 description 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
- 229950005741 rolipram Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- FTKTZRKAVSDSRA-UHFFFAOYSA-N sercloremine Chemical compound C1CN(C)CCC1C1=CC2=CC(Cl)=CC=C2O1 FTKTZRKAVSDSRA-UHFFFAOYSA-N 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- GVPIXRLYKVFFMK-UHFFFAOYSA-N setiptiline Chemical compound C12=CC=CC=C2CC2=CC=CC=C2C2=C1CN(C)CC2 GVPIXRLYKVFFMK-UHFFFAOYSA-N 0.000 description 1
- 229950002275 setiptiline Drugs 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- CKHJPWQVLKHBIH-ZDSKVHJSSA-N sulbutiamine Chemical compound C=1N=C(C)N=C(N)C=1CN(C=O)C(/C)=C(/CCOC(=O)C(C)C)SS\C(CCOC(=O)C(C)C)=C(\C)N(C=O)CC1=CN=C(C)N=C1N CKHJPWQVLKHBIH-ZDSKVHJSSA-N 0.000 description 1
- 229960003211 sulbutiamine Drugs 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 229960003708 sumatriptan Drugs 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 229940118176 surmontil Drugs 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- JJSHYECKYLDYAR-UHFFFAOYSA-N thozalinone Chemical compound O1C(N(C)C)=NC(=O)C1C1=CC=CC=C1 JJSHYECKYLDYAR-UHFFFAOYSA-N 0.000 description 1
- 229960005138 tianeptine Drugs 0.000 description 1
- 229960001312 tiaprofenic acid Drugs 0.000 description 1
- 229950008817 tiflucarbine Drugs 0.000 description 1
- BNKIWXODDDABSJ-UHFFFAOYSA-N tiflucarbine Chemical compound N1C2=CC(F)=C3SC=C(C)C3=C2C2=C1CCN(CC)C2 BNKIWXODDDABSJ-UHFFFAOYSA-N 0.000 description 1
- 229960001402 tilidine Drugs 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 229950010076 tofenacin Drugs 0.000 description 1
- PNYKGCPSFKLFKA-UHFFFAOYSA-N tofenacin Chemical compound C=1C=CC=C(C)C=1C(OCCNC)C1=CC=CC=C1 PNYKGCPSFKLFKA-UHFFFAOYSA-N 0.000 description 1
- 229960002501 tofisopam Drugs 0.000 description 1
- 229940041597 tofranil Drugs 0.000 description 1
- 229960002309 toloxatone Drugs 0.000 description 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
- PHTUQLWOUWZIMZ-GZTJUZNOSA-N trans-dothiepin Chemical compound C1SC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 PHTUQLWOUWZIMZ-GZTJUZNOSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- YDGHCKHAXOUQOS-BTJKTKAUSA-N trimipramine maleate Chemical compound [O-]C(=O)\C=C/C([O-])=O.C1CC2=CC=CC=C2[NH+](CC(C[NH+](C)C)C)C2=CC=CC=C21 YDGHCKHAXOUQOS-BTJKTKAUSA-N 0.000 description 1
- 239000003174 triple reuptake inhibitor Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 229960001968 veralipride Drugs 0.000 description 1
- RYJXBGGBZJGVQF-UHFFFAOYSA-N veralipride Chemical compound COC1=CC(S(N)(=O)=O)=CC(C(=O)NCC2N(CCC2)CC=C)=C1OC RYJXBGGBZJGVQF-UHFFFAOYSA-N 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 229960001255 viloxazine Drugs 0.000 description 1
- 229950006360 viqualine Drugs 0.000 description 1
- XFXANHWIBFMEOY-JKSUJKDBSA-N viqualine Chemical compound C12=CC(OC)=CC=C2N=CC=C1CCC[C@@H]1CCNC[C@@H]1C=C XFXANHWIBFMEOY-JKSUJKDBSA-N 0.000 description 1
- 229940045977 vivactil Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229960002791 zimeldine Drugs 0.000 description 1
- OYPPVKRFBIWMSX-SXGWCWSVSA-N zimeldine Chemical compound C=1C=CN=CC=1C(=C/CN(C)C)\C1=CC=C(Br)C=C1 OYPPVKRFBIWMSX-SXGWCWSVSA-N 0.000 description 1
- 229940020965 zoloft Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
In certain embodiments, the invention relates to methods for treating migraine (e.g. episodic migraine, chronic migraine, retinal migraine, ophthalmoplegic migraine, acephalgic migraine, migrainous disorder, menstrual migraine, abdominal migraine, childhood periodic syndromes, or cluster headache) by administering a peptide NMDAR partial agonist. In certain embodiments, the invention also relates to methods for treating or ameliorating long-term post migraine sequelae in a patient by administering a peptide NMDAR partial agonist. In certain other embodiments, the invention relates to methods for treating, suppressing, or preventing cortical spreading depression or a disease or condition caused by cortical spreading depression in a patient in need thereof, comprising administering a peptide NMDAR partial agonist. For example, provided herein are methods of treating epilepsy, traumatic brain injury, and/or stroke.
Description
2 METHODS OF TREATING OR AMELIORATING MIGRAINE
CROSS REFERENCE TO RELATED APPLICATIONS
[00011 This application claims the benefit and priority to United States Provisional Application No. 62/015,727, filed June 23, 2014, and United States Provisional Application No. 62/109,386, filed January 29, 2015, each of which are hereby incorporated by reference in their entirety.
BACKGROUND
100021 Migraine is a primary, episodic headache pain disorder associated with debilitating attacks that are recurring, and often poorly controlled by existing phannacotherapies that focus on vascular triggers. The onset of migraine attacks is often presaged by a scintillating scotoma, or migraine aura, caused by the phenomenon of cortical spreading depression (SD; see Ayata, Headache, 50:725-30, 2010; Eike _________________________________________ man-Haerter et al., Cum Neurol. Neurosci. Rep., 10:167-73, 2010; and Sanchez-del-Rio et al., Curr. Opin. Neurol., 17(3):289-93, 2004). SD
is a slowly propagating suppression of electrocorticographic activity triggered by a local increase in extracellular potassium and release of glutamate that produces a self-propagating wave of slow depolarization across large regions of cortex. Migraine with aura is experienced by approximately 15-30% of migraine sufferers.
[00031 The central nervous system (C,'NS) of mammals employs many neuroactive peptides to effect specialized signaling within the brain and spinal cord including the neuroactive peptides somatostatin, cholecystokinin, VIP, Substance P. enkephalin, Neuropeptide Y (NPY), Neurotensin, TRH, CCK, and dynorphin. (see generally The Biochemical Basis of Neuropharmacology, Cooper, Bloom and Roth, 5th ed.., Oxford University Press, New York, 1986). The careful elucidation of the complex signaling pathways, which operate in the C,NS, has led to identification of specific receptors modulated by these neuroactive peptides presenting important therapeutic targets for various disorders associated with the CNS.
[00041 The N-ineth,,,I-D-aspartate (NMDA) receptor (NMDAR), is one such receptor that has been implicated in neurodegenerative disorders including stroke-related brain cell death, convulsive disorders, and learning and memory. NMDAR also plays a central role in modulating normal synaptic transmission, synaptic plasticity, and ex.citotoxicity in the central nervous system. The NMDAR is further involved in long-term potentiation (L.TP). LTP is the persistent strengthening of neuronal connections that underlie learning and memory (See Bliss and Collingridge, 1993, Nature 361:31-39).
[00051 Two general classes of glutamate receptors have been characterized in the central nervous system (CNS). They are the metabotropic glutamate receptors, which belong to the G-protein coupled receptor family of signaling proteins, and the ionotropic glutamate receptors (Muir and Lees. Stroke, 1995, 26, 503-513). The ionotropic class is further subdivided into the AMPA, kainate, and NINADA receptor subtypes by the selective ligands that activate them.
[00061 NMDA-modulating small molecule agonist and antagonist compounds have been developed for potential therapeutic use. However, many of these are associated with very narrow therapeutic indices and undesirable side effects including hallucinations, ataxia, irrational behavior, and significant toxicity, all of which limit their effectiveness and/or safety.
[00071 Thus, there remains a need for improved treatments of migraine and other related diseases with compounds that provide increased efficacy and reduced undesirable side effects.
SUMMARY
[00081 In certain embodiments, the disclosure relates to a method of treating migraine, comprising administering to a patient in need thereof a pharmaceutically effective amount of a GLYX peptide. in certain embodiments, the migraine may be episodic migraine, chronic migraine, retinal migraine, ophthalmoplegic migraine, acephaigic migraine, migrainous disorder, menstrual migraine, abdominal migraine, childhood periodic syndromes, and/or cluster headache. In certain embodiments, the migraine is migraine without aura (common migraine). In certain embodiments, the migraine is migraine with aura (classical migraine). In certain embodiments, the migraine is accompanied by allodynia.
[00091 For example, the disclosed compounds may functionally interact with or modulate the action of the glycine site of the NMDAR for the -treatment of migraine (e.g., episodic migraine, chronic migraine, retinal migraine, ophthahnoplegic migraine, acephalg,ic migraine, migrainous disorder, menstrual migraine, abdominal migraine, childhood periodic syndromes, or cluster headache).
CROSS REFERENCE TO RELATED APPLICATIONS
[00011 This application claims the benefit and priority to United States Provisional Application No. 62/015,727, filed June 23, 2014, and United States Provisional Application No. 62/109,386, filed January 29, 2015, each of which are hereby incorporated by reference in their entirety.
BACKGROUND
100021 Migraine is a primary, episodic headache pain disorder associated with debilitating attacks that are recurring, and often poorly controlled by existing phannacotherapies that focus on vascular triggers. The onset of migraine attacks is often presaged by a scintillating scotoma, or migraine aura, caused by the phenomenon of cortical spreading depression (SD; see Ayata, Headache, 50:725-30, 2010; Eike _________________________________________ man-Haerter et al., Cum Neurol. Neurosci. Rep., 10:167-73, 2010; and Sanchez-del-Rio et al., Curr. Opin. Neurol., 17(3):289-93, 2004). SD
is a slowly propagating suppression of electrocorticographic activity triggered by a local increase in extracellular potassium and release of glutamate that produces a self-propagating wave of slow depolarization across large regions of cortex. Migraine with aura is experienced by approximately 15-30% of migraine sufferers.
[00031 The central nervous system (C,'NS) of mammals employs many neuroactive peptides to effect specialized signaling within the brain and spinal cord including the neuroactive peptides somatostatin, cholecystokinin, VIP, Substance P. enkephalin, Neuropeptide Y (NPY), Neurotensin, TRH, CCK, and dynorphin. (see generally The Biochemical Basis of Neuropharmacology, Cooper, Bloom and Roth, 5th ed.., Oxford University Press, New York, 1986). The careful elucidation of the complex signaling pathways, which operate in the C,NS, has led to identification of specific receptors modulated by these neuroactive peptides presenting important therapeutic targets for various disorders associated with the CNS.
[00041 The N-ineth,,,I-D-aspartate (NMDA) receptor (NMDAR), is one such receptor that has been implicated in neurodegenerative disorders including stroke-related brain cell death, convulsive disorders, and learning and memory. NMDAR also plays a central role in modulating normal synaptic transmission, synaptic plasticity, and ex.citotoxicity in the central nervous system. The NMDAR is further involved in long-term potentiation (L.TP). LTP is the persistent strengthening of neuronal connections that underlie learning and memory (See Bliss and Collingridge, 1993, Nature 361:31-39).
[00051 Two general classes of glutamate receptors have been characterized in the central nervous system (CNS). They are the metabotropic glutamate receptors, which belong to the G-protein coupled receptor family of signaling proteins, and the ionotropic glutamate receptors (Muir and Lees. Stroke, 1995, 26, 503-513). The ionotropic class is further subdivided into the AMPA, kainate, and NINADA receptor subtypes by the selective ligands that activate them.
[00061 NMDA-modulating small molecule agonist and antagonist compounds have been developed for potential therapeutic use. However, many of these are associated with very narrow therapeutic indices and undesirable side effects including hallucinations, ataxia, irrational behavior, and significant toxicity, all of which limit their effectiveness and/or safety.
[00071 Thus, there remains a need for improved treatments of migraine and other related diseases with compounds that provide increased efficacy and reduced undesirable side effects.
SUMMARY
[00081 In certain embodiments, the disclosure relates to a method of treating migraine, comprising administering to a patient in need thereof a pharmaceutically effective amount of a GLYX peptide. in certain embodiments, the migraine may be episodic migraine, chronic migraine, retinal migraine, ophthalmoplegic migraine, acephaigic migraine, migrainous disorder, menstrual migraine, abdominal migraine, childhood periodic syndromes, and/or cluster headache. In certain embodiments, the migraine is migraine without aura (common migraine). In certain embodiments, the migraine is migraine with aura (classical migraine). In certain embodiments, the migraine is accompanied by allodynia.
[00091 For example, the disclosed compounds may functionally interact with or modulate the action of the glycine site of the NMDAR for the -treatment of migraine (e.g., episodic migraine, chronic migraine, retinal migraine, ophthahnoplegic migraine, acephalg,ic migraine, migrainous disorder, menstrual migraine, abdominal migraine, childhood periodic syndromes, or cluster headache).
3 [00101 In certain embodiments, the disclosure relates to a method of treating, suppressing and/or preventing cortical spreading depression (SD), comprising administering to a patient in need thereof a pharmaceutically effective amount of a GLYX peptide. In certain embodiments, the disclosure relates to treating or ameliorating long-term post migraine sequelae in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of GLYX peptide.
[00111 In certain embodiments, the GLYX peptide has the following structure:
H
-1µ
H2t\kõ.õ0---, N "
_I/ Li 0 NH2 OH
Or a pharmaceutically acceptable salt thereof, Of derivative thereof having NMDAR partial agonist activity.
[0012] In one aspect, the invention relates to a method for -treating migraine in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound represented by:
o 0, H
-OH
or pharmaceutically acceptable salt thereof.
[00131 In another aspect, the invention relates to a method of treating, suppressing, and/or preventing cortical spreading depression in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound represented by:
- N
je 0 NH, 'OH
or pharmaceutically acceptable salt thereof
[00111 In certain embodiments, the GLYX peptide has the following structure:
H
-1µ
H2t\kõ.õ0---, N "
_I/ Li 0 NH2 OH
Or a pharmaceutically acceptable salt thereof, Of derivative thereof having NMDAR partial agonist activity.
[0012] In one aspect, the invention relates to a method for -treating migraine in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound represented by:
o 0, H
-OH
or pharmaceutically acceptable salt thereof.
[00131 In another aspect, the invention relates to a method of treating, suppressing, and/or preventing cortical spreading depression in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound represented by:
- N
je 0 NH, 'OH
or pharmaceutically acceptable salt thereof
4 [00141 In another aspect, the invention relates to a method of treating or ameliorating long-term post migraine sequelae in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound represented by:
H2N' OH
0 (j:
[00151 or pharmaceutically acceptable salt thereof.
10016] As described in greater detail below, drugs that are effective when administered at aura would be beneficial to a patient, e.g., by allowing intervention at an earlier stage of migraine. it is contemplated that the methods described herein are applicable to the treatment of migraine with aura comprising administration of a GLYX peptide at aura.
BRIEF DESCRIPTION OF FIGURES
10017] Figure 1 shows focal, high [I0-induced spreading depression (SD) in field CA1 of hippocampal slices resulting in a change in luminance reflecting the spreading wave of mass depolarization of neurons and glia.
[00181 Figure 2 shows data for SD elicited in brain slices; there were no significant differences between the baseline areas of individual sequential episodes of SD
at the initiating site (Bonferroni Multiple Comparison Test, P >0.20), indicating that CiLYX-13 did not alter the initiation of SD.
[00191 Figure 3 shows data demonstrating that CiLYX-13 increases the refractory period for SD initiation. SD could be successfully evoked five minutes after a previous SD in a control slice (Control), but could not be elicited in a slice treated with GLYX-1 3 (GLYX-13 30').
100201 Figure 4A shows that an SD "aura" of increased luminance spreads from the initiating pipette and propagates across the slice, and can be used to calculate SD conduction -velocity (Figure 4B).
[0021.1 Figure 5 shows one-way analysis of variance (ANOVA) with repeated measures to analyze 6 subsequent SDs in order to test whether repeated episodes of SD
maintained a stable speed and if GLYX-13 affected SD conduction velocity.
100221 Figure 6A shows spine shrinkage in response to two episodes of SD
in a control pyramidal neuron, while Figure 6B exemplifies the same process in the presence of 10 MM
I,YX-13; Figure 6C indicates that GLYX-13 rescued recovery of spine size following SD.
10023] Figure 7A shows spreading distance and Figure 7B shows spreading velocity of
H2N' OH
0 (j:
[00151 or pharmaceutically acceptable salt thereof.
10016] As described in greater detail below, drugs that are effective when administered at aura would be beneficial to a patient, e.g., by allowing intervention at an earlier stage of migraine. it is contemplated that the methods described herein are applicable to the treatment of migraine with aura comprising administration of a GLYX peptide at aura.
BRIEF DESCRIPTION OF FIGURES
10017] Figure 1 shows focal, high [I0-induced spreading depression (SD) in field CA1 of hippocampal slices resulting in a change in luminance reflecting the spreading wave of mass depolarization of neurons and glia.
[00181 Figure 2 shows data for SD elicited in brain slices; there were no significant differences between the baseline areas of individual sequential episodes of SD
at the initiating site (Bonferroni Multiple Comparison Test, P >0.20), indicating that CiLYX-13 did not alter the initiation of SD.
[00191 Figure 3 shows data demonstrating that CiLYX-13 increases the refractory period for SD initiation. SD could be successfully evoked five minutes after a previous SD in a control slice (Control), but could not be elicited in a slice treated with GLYX-1 3 (GLYX-13 30').
100201 Figure 4A shows that an SD "aura" of increased luminance spreads from the initiating pipette and propagates across the slice, and can be used to calculate SD conduction -velocity (Figure 4B).
[0021.1 Figure 5 shows one-way analysis of variance (ANOVA) with repeated measures to analyze 6 subsequent SDs in order to test whether repeated episodes of SD
maintained a stable speed and if GLYX-13 affected SD conduction velocity.
100221 Figure 6A shows spine shrinkage in response to two episodes of SD
in a control pyramidal neuron, while Figure 6B exemplifies the same process in the presence of 10 MM
I,YX-13; Figure 6C indicates that GLYX-13 rescued recovery of spine size following SD.
10023] Figure 7A shows spreading distance and Figure 7B shows spreading velocity of
5 spreading depression (in estrogen-treated and non-oil treated) rats indicating that spreading speed was faster as compared to oil-treated rats.
100241 Figure 8 shows that SD in slices from estrogen treated rats traveled longer than oil-treated rats.
100251 Figure 9A shows that luminance changes associated with SD in a rat experiment were delayed in the presence of GLYX-13; Figure 9B indicates SD was evoked in the presence of GLYX-13.
100261 Figure 10 shows the effect of GLYX-13 on SD propagation speed across from estrogen treated rats before and after application of GLYX-13 (F(1,8)=3.1;p<0.05); and the preexposure of GLYX-13 between the two groups (F(1,8)=4.2; p<0.05).
is [0027] Figures 11A-11B show rescue of blast-induced learning deficits by rapas-linel (3 mg/kg IV; I hour pest-blast) in PEI, tests 24 hours post-blast.. Figure I IA
shows blast recovery time (latency to normal ambulation) data. Figure I 113 shows the results of a single 3 min Positive Emotional Learning (PEL) test session conducted 24 hours post-blast using a between subjects design. N = 4-6 per group. * P < 0.05 (Figure 1 IA) ANOVA, or (Figure I1B) fisher's PLSD post hoc test, rapastinel TEl vs. vehicle + TBL
DETAILED DESCRIPTION
Migraine Classifications 100281 Migraines were first comprehensively classified in 1988. The international Headache Society most recently updated their classification of headaches in 2004. According to this classification migraines are primary headaches along with -tension-type headaches and cluster headaches, among others.
[00291 Migraines are divided into seven subclasses (some of which include further subdivisions):
100241 Figure 8 shows that SD in slices from estrogen treated rats traveled longer than oil-treated rats.
100251 Figure 9A shows that luminance changes associated with SD in a rat experiment were delayed in the presence of GLYX-13; Figure 9B indicates SD was evoked in the presence of GLYX-13.
100261 Figure 10 shows the effect of GLYX-13 on SD propagation speed across from estrogen treated rats before and after application of GLYX-13 (F(1,8)=3.1;p<0.05); and the preexposure of GLYX-13 between the two groups (F(1,8)=4.2; p<0.05).
is [0027] Figures 11A-11B show rescue of blast-induced learning deficits by rapas-linel (3 mg/kg IV; I hour pest-blast) in PEI, tests 24 hours post-blast.. Figure I IA
shows blast recovery time (latency to normal ambulation) data. Figure I 113 shows the results of a single 3 min Positive Emotional Learning (PEL) test session conducted 24 hours post-blast using a between subjects design. N = 4-6 per group. * P < 0.05 (Figure 1 IA) ANOVA, or (Figure I1B) fisher's PLSD post hoc test, rapastinel TEl vs. vehicle + TBL
DETAILED DESCRIPTION
Migraine Classifications 100281 Migraines were first comprehensively classified in 1988. The international Headache Society most recently updated their classification of headaches in 2004. According to this classification migraines are primary headaches along with -tension-type headaches and cluster headaches, among others.
[00291 Migraines are divided into seven subclasses (some of which include further subdivisions):
6 [00301 Migraine without aura, or "common migraine", involves migraine headaches that are not accompanied by an aura.
10031] Migraine with aura, or "classic migraine", usually involves migraine headaches accompanied by an aura. Less commonly, an aura can occur without a headache, or with a nonmigraine headache. Two other varieties are familial hemiplegic migraine and sporadic hemiplegic migraine, in which a person has migraines with aura and with accompanying motor weakness. if a close relative has had the same condition, it is called "familial", otherwise it is called "sporadic". Another variety is basilar-type migraine, where a headache and aura are accompanied by difficulty speaking, world spinning, ringing in. ears, or a number of other brainstem-related symptoms, but not motor weakness. This type was initially believed to be due to spasms of the basilar artery, the artery that supplies the brains-tem.
Guidelines for diagnosis of migraine with aura are found, for example, in Eriksen. et al., European Journal of Neurology 11 :583-591, 2004 and in the international Classification of Headache Disorders, Second Edition KHD-H). Subtypes of migraine with aura include those set forth in the IdHD-ii such as typical aura with migraine headache (1HS 1.2.1), typical aura with non-migraine headache (THS 1.2.2), typical aura without headache OHS 1.2.3), familial hemiplegic migraine (IRS
1.2.4), sporadic hemiplegic migraine OHS 1.2.5), and basilar-type migraine (fliS 1.2.6).
[00321 Childhood periodic syndromes that are commonly precursors of migraine include cyclical vomiting (occasional intense periods of vomiting), abdominal migraine (abdominal pain, usually accompanied by nausea), and benign paroxysmal vertigo of childhood (occasional attacks of vertigo).
100331 Retinal migraine involves migraine headaches accompanied by visual disturbances or even temporary blindness in one eye.
[00341 Complications of migraine describe migraine headaches and/or auras that are unusually long or unusually frequent, or associated with a seizure or brain lesion.
100351 Probable migraine describes conditions that have some characteristics of migraines, but where there is not enough evidence to diagnose it as a migraine with certainty (in the presence of concurrent medication overuse).
[00361 Chronic migraine is a complication of migraines, and is a headache that fulfills diagnostic criteria for migraine headache and occurs for a greater time interval. Specifically, greater or equal to 15 days/month for longer than 3 months.
[0037] There are four possible phases to a migraine, although not all the phases are necessarily experienced: (1) The prodrome, which occurs hours or days before the headache;
(2) The aura, which immediately precedes the headache; (3) The pain phase, also known as headache phase; and (4) The postdrome, the effects experienced following the end of a migraine attack.
[0038] Prodromal or premonitory symptoms occur in ¨60% of those with migraines with an onset of two hours to two days before the start of pain or the aura. These symptoms may include a wide variety of phenomena including: altered mood, irritability, depression or euphoria, fatigue, craving for certain food, stiff muscles (especially in the neck), constipation or diarrhea, and sensitivity to smells or noise. This may occur in those with either migraine with aura or migraine without aura.
[00391 An aura is a transient focal neurological phenomenon that occurs before or during the headache. They appear gradually over a number of minutes and generally last fewer than 60 minutes. Symptoms can be visual, sensory or motor in nature and many people experience more than one. Visual effects OCCUr most frequently; they occur in up to 99?/o of cases and in more than 50% of cases are not accompanied by sensory or motor effects. Vision disturbances often consist of a scintillating scotoma (an area of partial alteration in the field of vision which flickers and may interfere with a person's ability to read or drive.) These typically start near the center of vision and then spread out to the sides with zigzagging lines which have been described as looking like fortifications or walls of a castle. Usually the lines are in black and white but some people also see colored lines. Some people lose part of their field of vision (known as hemianopsia) while others experience blurring.
[00401 Sensory aurae are the second most common type; they occur in 30-40% of people with auras. Often a feeling of pins-and-needles begins on one side in the hand and arm and spreads to the nose-mouth area on the same side. Numbness usually occurs after the tingling has passed with a loss of position sense. Other symptoms of the aura phase can include: speech or language disturbances, world spinning, and less commonly motor problems Motor symptoms indicate that this is a hemiplegic migraine, and weakness often lasts longer than one hour unlike other auras.
[0041] An aura may also occur without a subsequent headache. Acephalgic migraines, also known as silent migraines, are relatively rare and include an aura and other symptoms but without a subsequent headache (i.e., no pain phase).
[00421 During the pain phase, the headache usually is unilateral, throbbing, and moderate to severe in intensity. It usually com.es on gradually and is aggravated by physical activity. In more than 40% of cases however the pain may be bilateral, and neck pain is commonly associated. Bilateral pain is particularly common in those who have migTaines .without an aura.
Less commonly pain may occur primarily in the back of top of the head. The pain usually lasts 4 to 72 hours in adults, however in young children frequently lasts less than 1 hour. The frequency of attacks is variable, from a few in a lifetime to several a week, with the average being about one a month.
[00431 The pain is frequently accompanied by nausea, vomiting, sensitivity to light, sensitivity to sound, sensitivity to smells, fatigue and irritability. in a basilar migraine, a migraine with neurological symptoms related to the brain stem or with neurological symptoms on both sides of the body, common effects include: a sense of the world spinning, light-headedness, and confusion. Nausea occurs in almost 90% of people, and vomiting occurs in about one-third. Other symptoms may include: blurred vision, nasal stuffiness, diarrhea, frequent urination, pallor, or sweating. Swelling or tenderness of the scalp ma:yr occur as can neck stiffness.
[0044] The effects of migraine may persist for some days after the main headache has ended; this is called the migraine postdrome. Many report a sore feeling in the area where the migraine was, and some report impaired thinking for a few days after the headache has passed.
The patient may feel tired and have head pain, cognitive difficulties, gastrointestinal symptoms, mood changes, and weakness.
GLYX Peptides [0045] GLYX-l3 is a newly-developed rapid-acting, long-lasting antidepressant with unprecedented modulatory actions on the activation of N-methyl-D-aspartate glutamate receptors (NMDAR). This agent, which acts at the obligatory co-agonist glycine site on the NA/IDA receptor required for it to be activated, normalizes activation of this critical receptor, increasing it when it is too low, and suppressing it when it is too high.
Through this action, GLYX-13 can enhance the induction of long-term potentiation (LTP), while suppressing LTD, of synaptic strength, and restore normal LTP in hippocampal slices from aging animals.
[00461 As used :herein, the term "GLYX peptide" refers to a peptide having NMDAR
glycine-site partial agonistlantagonist activity. GLYX peptides may be obtained by well-known recombinant or synthetic methods such as those described in US Patents 5,763,393 and 4,086,196 herein incoiporated by reference. In some embodiments, GLYX refers to a tetrape tide having the amino acid sequence Thr-Pro-Pro-Thr, or L-threonyl-L-prolyl-L-prolyl-1.0 L-threonine amide.
l00471 For example, GLYX-13 refers to the compound depicted as:
= oo, 0 H
H 2N ,kk N N H 2 N N
H
Formula I
[00481 Also contemplated are polymorpbs, homologs, hydrates, solvates, free bases, and/or suitable salt forms of GLYX-13 such as, but not limited to, the acetate salt.
The peptide may be cyclized or non-cyclized form as further described in US 5,763,393. In some embodiments, an a GLYX-13 analog may include an insertion or deletion of a moiety on one or more of the Tin or Pro groups such as a deletion of CH2, OH, or NI712 moiety. in other embodiments, GLYX-13 may be optionally substituted with one or more halogens, CI-C3 alkyl (optionally substituted with halogen or amino), hydroxyl, andior amino. Glycine-site partial agonist of the NMDAR
are disclosed in US 5,763,393, US 6,107,271, and Wood et al., NeuroReport, 19, 1059-1061, 2008, the entire contents of which are herein incorporated by reference.
l00491 It may be understood that the peptides disclosed here can include both natural and unnatural amino acids, e.g., all natural amino acids (or derivatives thereof), all unnatural amino acids or derivatives thereof), or a mixture of natural and unnatural amino acids. For example, one, two, -three or more of the amino acids in GLYX-13 may each have, independently, a D- or -L-configurati on.
[0050] GLYX-13 may act predominantly at NR2B-contairting NMDARs, and may not display the classic side effects of known NMDAR modulators such as CPC-101,606 and 5 ketamine in certain embodiments, an anti-migraine or other therapeutic effect with essentially no sedation may be produced by GLYX- I 3 when administered to a subject in therapeutically effective amounts. In still other embodiments, CiLYX-13 may not have abuse potential (e.g., may not be habit-forming).
[0051] In some embodiments, GLYX-13 may increase AMPA GluRl serine-845 10 phosphorylation. In certain embodiments, glycogen synthase kinase 3 (GSK-30) may be activated by GLYX-13. In some cases, levels of 13-catenin may be altered after administration of GLYX-13.
[00521 In some embodiments, GLYX-13 or a composition comprising GLYX-13 may provide better i.v. in vivo potency and/or brain level concentration, relative to plasma levels.
[0053] Additionally, GLYX-13 may have a wide therapeutic index compared to glycine site antagonists such as L-701,324, or other gl:,,,cine site antagonists having narrow therapeutic indexes, which result in a very narrow range of dose between therapeutic effects and ataxia. For example, L-701,324 had anticonvulsant effects at doses that produced ataxia (Bristow, et al.
PET 279:492-501, 1996). Similarly, a series of Wierz compounds had anticonvuisant effects at doses that produced ataxia (Parsons, et al., JPET283:1264-1275, 1997).
Methods [00541 in one aspect, the invention relates to a method for treating migraine in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound represented by:
0 y NC:
'OH
or pharmaceutically acceptable salt thereof i [00551 In certain embodiments, the compound is administered to the patient with a dose of about 0.01 inivikg to about 1000 mg/kg or about 1 mg/kg to about 500 mg/kg of the compound.
10056] In certain embodiments, the migraine is episodic migraine, chronic migraine, retinal migraine, ophthahnoplegic migraine, acephalgic migraine, migrainous disorder, menstrual migraine, abdominal migraine, childhood periodic syndromes, or cluster headache.
[00571 In certain embodiments, the migraine is episodic migraine, chronic migraine, retinal migraine, oplithalnroplegic migraine, acephalgic migraine, or cluster headache.
10058[ In certain embodiments, the migraine is migraine with aura (classical migraine.).
[0059j in certain embodiments, the migraine is migraine without aura (common migraine.).
[00601 In certain embodiments, the migraine is accompanied by allodynia.
[00611 In certain embodiments, the method comprises administering about I
to 10 mg/kg, about 10 mg/kg to about 250 mg/kg, about 20 mg/kg to about 150 mg/kg, about 30 mg/kg to about 125 mg/kg, about 40 -mg/kg to about 110 mg/kg, about 50 mg/kg to about 100 mg/kg, about 60 mg/kg to about 90 mg/kg, or about 70 mg/kg to about 90 mg/kg, of the compound.
[00621 In certain embodiments, the method comprises administering about 1 mg/kg, about 2.5 mg/kg, about 5 mg/kg, about 10 mg/kg, about 15 -mg/kg, about 20 mg/kg, about 25 -mg/kg, about 30 mg/kg, about 50 mg/kg, about 70 mg/kg, or about 100 mg/kg of the compound.
10063] In certain embodiments, the method comprises administering the compound about twice a day, about every day, every 2 days, every 3 days, every 4 days, every 5 days, about once a week, about every two weeks, or about every four weeks.
[00641 In another aspect, the invention relates to a method of treating, suppressing, Of preventing cortical spreading depression or a disease or condition caused by cortical spreading depression in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound represented by:
OH
`eõ..
Li NH 2 'OH
or pharmaceutically acceptable salt thereof.
[00651 In another aspect, the invention relates to a method of treating Of ameliorating long-term post migraine sequel.ac in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound represented by:
H
'Nts H2Nh-N,It's `^"OH
or pharmaceutically acceptable salt thereof [0066] in certain embodiments, the compound is administered to the patient with a dose of about 0.01 ing/k.g to about 1000 mg/kg of the compound. In certain embodiments, the compound is administered to the patient with a dose of about 1 mg/kg to about 500 mg/kg of the compound.
[00671 In certain embodiments, the method comprises administering about 1 mg/kg to 10 -mg/kg, about 1 mg/kg to 20 mg/kg; about 10 mg/kg to about 250 mg/kg, about 20 mg/kg to about 150 mg/kg, about 30 mg/kg to about 125 mg/kg, about 40 mg/kg to about 110 mg/kg, about 50 mg/kg to about 100 mg/kg, about 60 mg/kg to about 90 mg/kg, or about 70 mg/kg to about 90 mg/kg, of the compound.
l00681 In certain embodiments, the method comprises administering about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 50 mg/kg, about 70 mg/kg, 1 mg/kg, 5 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg or about 100 mg/kg of the compound.
[00691 In certain embodiments, the method comprises administering the compound about twice a day, about every day, every 2 days, every 3 days, every 4 days, every 5 days, about once a week, or about every two weeks, or e.g., every month.
[00701 In certain embodiments, the method further comprises co-administration with an opioid, an antidepressant, an antiepileptic, a non-steroidal anti-inflammatory drug (NSAID), a serutonin 5E1T IB/1D agonist, an N-methyl-D-aspartate antagonist, or an anti-inflammatory compound.
[00711 NMDAR activation may promote or even be essential for, the phenomenon of SD in many experimental situations. Therefore, compounds that prevent over-activation of NNIDARs could be important new therapies for lessening, and even preventing, the onset of migraine attacks. For example, CiLYX-13, discussed below, suppresses the production and propagation of SD in hippocampal slices in vitro. In certain experiments, GLYX-13 may completely prevent the induction of SD by local increase in extracellular potassium concentration, and/or if not blocking it completely, may slow the rate of SD propagation. Furthermore, CILYX-13 can improve the return of dendritic spines to their original sizes following an SD. For example, provided herein are methods of treating migraine in patients prophylacticly and/or on an acute basis. Such administration may ameliorate the severity (or in some embodiments, abort) migraine attacks in patients.
[00721 In certain embodiments, the patient is a human. Contemplated patients include female patients and/or adolescent patients.
[00731 Also provided herein arc methods of treating migraine (e.g., episodic migraine, chronic migraine, retinal migraine, ophthalmoplegic migraine, acephalgic migraine, migrainous disorder, menstrual migraine, abdominal migraine, childhood periodic syndromes, or cluster headache) in neatment-resistant patients or treating refractory migraines, e.g., patients suffering from a migraine that does not, andlor has not, responded to adequate courses of at least one, or at least two, other compounds or therapeutics. For example, provided herein is a method of treating migraine (e.g., episodic migraine, chronic migraine, retinal migraine, ophthalmoplegic migraine, acephalgic migraine, migrainous disorder, menstrual migraine, abdominal migraine, childhood periodic syndromes, or cluster headache) in a treatment resistant patient, comprising a) optionally identifying the patient as treatment resistant and b) administering an effective dose of GLYX-13 to said patient. In certain embodiments, the migraine is migraine with aura.
[00741 Provided herein, in an embodiment, are methods of acutely treating migraine (e.g., episodic migraine, chronic migraine, retinal migraine, ophthalmoplegic migraine, acephalgic migraine, migrainous disorder, menstrual migraine, abdominal migraine, childhood periodic syndromes, or cluster headache) in a patient in need thereof, comprising administering an effective amount of a GLYX peptide, for example, in a single unit dose. For example, contemplated herein in an embodiment, is a method of treating migraine in a patient in need thereof at the onset of a migraine attack comprising administering acutely (e.g., a single dose) an effective amount of GLYX-13. Such methods may relieve the patient of at least one symptom of migraine for about 2 weeks or less, 1 week or less, 1 day or less, or 1 hour or less (e.g. 15 minutes or less, half an hour or less), after said administration. In some embodiments, such methods may relieve the patient of at least one symptom of migraine for about 1 day or more, I week or more, or 2 weeks or more after said administration. For example, provided herein is a method comprising administering an. effective amount of a GLYX
peptide to a patient suffering from migraine, wherein said patient is substantially relieved of at least one symptom of migraine substantially earlier after the first administration of a GLYX peptide, as compared to the same patient administered another medicament for heating migraine. One of skill in the art will appreciate that such methods of acute administration may be advantageous in a hospital or oat-patient setting. The methods described herein can also be useful for the treatment of allodynia that occurs during migraine with aura.
[0075] The present methods may also be used in treatment of patients who have depression, suffer from traumatic brain injury, epilepsy, or are at risk of a stroke. For example, provided herein, in an. embodiment, is a method for treating traumatic brain, injury comprising administering an effective amount of a GLYX peptide, e.g., GLYX-13. In another embodiment, a method for treating epilepsy is provided, comprising administering an effective amount of a GLYX peptide, e.g., GLYX-13.
[0761 In addition to cardiovascular conditions, migraine sufferers with aura may be at increased risk for other neurological and/or psychological conditions and disorders. it has been shown., for example, that the co-occurrence of migraine with aura with major depression or a suicide attempt increased the risk of developing unprovoked seizure (Hesdorffer et al., Epilepsy Res. 75(2-3):220-223, 2007). Other conditions associated with migraine with aura include significantly higher markers of NO activity, increased incidence of depression, and genetic biomarker correlation for stroke substantially greater than that of the general population (Etminan et al., ttiv1J330(7482):63, 2005). A migraine sufferer that has, or is at risk of, any of these conditions may take medications to treat or to manage these diseases, and these medications may adversely interact with currently used medications for the treatment of migraine with aura. As shown herein, some of these conditions are contraindications for triptan therapy (e.g., stroke and sumatriptan therapy). Moreover, the FDA issued a public health advisory in 2006 regarding serotonin syndrome, a life-threatening condition that may occur when. a tripta.n is used together with certain anti-depressants that are serotonin reuptake inhibitors (SSR1s) or selective serotonin/norepinephrine reuptake inhibitors (SNRIs).
Accordingly, the methods described herein may be useful for the -treatment of patients who have depression or patients who have suffered, or are at risk of, stroke.
Dosages [00771 The dosage of any compositions of the disclosure will vary depending on the symptoms, age and body weight of the patient, the nature and severity of the disorder to be 5 treated or prevented, the route of administration, and the form of the subject composition. Any of the subject formulations may be administered in a single dose or in divided doses. Dosages for the compositions of the disclosure may be readily determined by techniques known to those of skill in the art or as taught herein. In general, satisfactory results can be obtained when the compound is administered to a human at a daily dosage of, for example, between 0.05 mg and 10 3000 mg (measured as the solid form), e.g. about 10 mg to about 500 mg, or e.g., about 1 to about 200mg/kg. Dose ranges include, for example, between 10-1000 mg (e.g., 50-800 mg). In some embodiments, 50, 100, 150, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, or 1000 mg of the compound is administered.
Alternatively, the dosage amount can be calculated using the body weight of the patient. For example, the dose of is a compound, or pharmaceutical composition thereof, administered to a patient may range from 1-500 mg/kg (e.g., 5-250 mg/kg). In exemplary, non-limiting embodiments, the dose may range from 5-200 mg/kg (e.g., 1, 2, 2.5, 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 mg/kg) or from 15-100 mg/kg (e.g., 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200 mg/kg). In exemplary, non-limiting embodiments, the dose may range from 1-15 mg/kg, 50-100 .mg/kg, 60-90 mg/kg, or 70-80 mg/kg.
[00781 GLYX-13 may provide a high therapeutic index. For example, GLYX-13 may be therapeutically effective with an i.v. or subcutaneous dose range of about 1 to about 10 mg/kg, about 10 to about 200 mg/kg, e.g. about 30 mg/kg, about 75 mg/kg, or about 100 mg/kg. In some embodiments, no ataxia occurs, at for example a dose of at 500 mg/kg, i.v.
[00791 A therapeutically effective amount of GLYX peptide required for use in therapy varies with the form of the condition being treated, the length of treatment time desired, the age and the condition of the patient, and is ultimately determined by the attending physician. The desired dose may be conveniently administered in a single dose that is effective for two weeks, one week, 6, 5, 4, 3, 2, or 1 day, or as multiple doses administered at appropriate intervals, for example as two, three, four or more sub-doses per day.
[00801 An effective dose or amount, and any possible effects on the timing of administration of the formulation, may need to be identified for any particular composition of the disclosure. This may be accomplished by routine experiment as described herein, using one or more groups of animals (preferably at least 5 animals per group), or in human trials if appropriate. The effectiveness of any subject composition and method of treatment or prevention may be assessed by administering the composition and assessing the effect of the administration by measuring one or more applicable indices, and comparing the post-treatment values of these indices to the values of the same indices prior to treatment.
[00811 The precise time of administration and amount of any particular subject composition that will yield the most effective treatment in a given patient will depend upon the activity, pharmacokinetics, and bioavailability of a subject composition, physiological condition of the patient (including age, sex, disease type and stage, general physical condition, responsiveness to a given dosage and type of medication), route of administration, and the like. The guidelines presented herein may be used to optimize the treatment, e.g., determining the optimum time and/or amount of administration, which will require no more than routine experimentation consisting of monitoring the subject and adjusting the dosage and/or timing.
100821 While the subject is being treated, the health of the patient may be monitored by measuring one or more of the relevant indices at predetermined times during the treatment period. Treatment, including composition, amounts, times of administration and formulation, may be optimized according to the results of such monitoring. The patient may be periodically reevaluated to determine the extent of improvement by measuring the same parameters.
Adjustments to the amount(s) of subject composition administered and possibly to the time of administration may be made based on these reevaluations.
10083] Treatment may be initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage may be increased by small increments until the optimum therapeutic effect is attained.
[00841 The use of the subject compositions may reduce the required dosage for any individual agent contained in the compositions because the onset and duration of effect of the different agents may be complimentary.
1 '7 [00851 Toxicity and therapeutic efficacy of subject compositions may be determined by standard pharmaceutical procedures in c;. 11 cultures or experimental animals, e.g., for determining the LD50 and the ED50.
100861 The data obtained from the cell culture assays and animal studies may be used in formulating a range of dosage for use in humans. The dosage of any subject composition lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For compositions of the disclosure, the therapeutically effective dose may be estimated initially from cell culture assays.
100871 in certain embodiments, the GLYX peptide is administered as a preventative measure (i.e., before the prodrome phase). -hi certain embodiments, the GLYX
peptide is administered during prodrome. in certain embodiments, the GLYX peptide is administered at aura. By "at aura" is meant any time after the onset of aura and prior to the onset of migraine pain. In certain embodiments, the GLYX peptide is administered after the onset of migraine pain. -hi certain embodiments, the (JINX peptide is administered during the postdrome, e.g. to lessen the symptoms thereof.
[00881 The term "prevent," as used herein, refers to prophylactic treatment or treatment that prevents one or more symptoms or conditions of a disease, disorder, or conditions described herein (e.g., pain or migraine with aura and with or without allodynia).
Preventative treatment can be initiated, for example, prior to ("preexposure prophylaxis") or following ("post-exposure prophylaxis") an event that precedes the onset of the disease, disorder, or conditions (e.g., at migraine aura). Preventive treatment that includes administration of a GLYX peptide described herein, or a pharmaceutically acceptable salt or solvate -thereof, or a pharmaceutical composition thereof, can be acute, short-term, or chronic. The doses administered may be varied during the course of preventative treatment. See also: Kaniecki et al., "Treatment of Primary Headache: Preventive Treatment of Migraine." In: Standards of Care for Headache Diagnosis and Treatment. Chicago (IL): National Headache Foundation; 2004, p.
40-52.
Formulations 100891 The GLYX peptides of the disclosure may be administered by various means, depending on their intended use, as is well known in the art. For example, if compositions of the disclosure are to be administered orally, they may be formulated as tablets, capsules, granules, powders or syrups. Alternatively, formulations of the disclosure may be administered parenterally as injections (intravenous, intramuscular or subcutaneous), drop infusion preparations, or suppositories. For application by the ophthalmic mucous membrane route, compositions of the disclosure may be formulated as eyedrops or eye ointments.
These formulations may be prepared by conventional means, and, if desired, the compositions may be mixed with any conventional additive, such as an excipient, a binder, a disintegrating agent, a lubricant, a corrigent, a solubilizing agent, a suspension aid, an.
emulsifying agent or a coating agent.
[00901 DNA encoding the GLYX peptides, incorporated into an expression vector, can also be administered, using any of the known administration methods, to express of the GLYX
peptides in vivo.
100911 in formulations of the subject invention, wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants may be present in the formulated agents.
[0092] Subject compositions may be suitable for oral, topical (including buccal and sublingual), rectal, vaginal, aerosol and/or parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of composition that may be combined with a carrier material to produce a single dose vary depending upon the subject being treated, and the particular mode of administration.
10093] Methods of preparing these formulations include the step of bringing into association compositions of the disclosure with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association agents with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
[00941 Formulations suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pasfilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia), each containing a predetermined amount of a subject composition thereof as an active ingredient.
Compositions of the disclosure may also be administered as a 'bolus, eleetuary, or paste.
[0095] In solid dosage forms for oral administration (capsules, tablets, pills, dragees, powders, granules and the like), the subject composition is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, marmitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, acetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonhe clay; (9) lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof: and (10) coloring agents. In the case of capsules, tablets and pills, the compositions may also comprise buffering agents.
Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
[00961 A. tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropyimethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the subject composition moistened with an inert liquid diluent.
Tablets, and other solid dosage forms, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art.
[00971 Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. in addition to the subject composition, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofinyl alcohol, polyethylene glycols and fatty acid esters of sorbitan, cyclodextrins and mixtures thereof 5 [00981 Suspensions, in addition to the subject composition, may contain. suspending agents as, for example, ethoxylated i.sostearyi alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof 10099] Formulations for rectal or vaginal administration may be presented as a suppository, 10 which rna,,, be prepared by mixing a subject composition with one or more suitable non--irritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the body cavity and release the active agent Formulations which are suitable for vaginal administration also include pessaries, tampons, 15 creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
[001001 Dosage forms for transdermal administration of a subject composition includes powders, sprays, ointments, pastes, creams, lotions, gels, solutions, and patches.
[001011 For topical ocular administration compositions of this invention may take the form 20 of solutions, gels, ointments, suspensions or solid inserts, formulated so that a unit dosage comprises a therapeutically effective amount of the active component or some multiple thereof in the case of a combination therapy.
[001021 Pharmaceutical compositions of this invention suitable for parenteral administration comprise a subject composition in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions Of emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
1001031 Examples of suitable aqueous and nun-aqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate and cyclodextrins. Proper fluidity may be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
Combination Therapy 1001041 Any of the GLYX peptides described herein (e.g., GLYX-13) can be used alone or in combination with other agents to treat or prevent any of the diseases or conditions discussed herein. For example, in some combination treatments, the dosages of one or more of the therapeutic compounds may be reduced from standard dosages when administered alone.
1001051 The methods of the invention also comprise co-administration of a GLYX
peptide with an opioid, an antidepressant, an antiepileptie, a non-steroidal anti-inflammatory drug (MAID), a serotonin 5HT1 B/1 D agonist, an N-methyl-D-aspartate antagonist, or an anti-inflammatory compound.
1001061 The disclosure relates in certain embodiments to the use of a GLYX
peptide or peptides alone or in combination with one or more other antidepressant treatments, such as tricyclic antidepressants, MAO-I's, SSR1's, and double and triple uptake inhibitors and/or anxiolytic drugs for manufacturing a medicament for treating migraine (e.g., episodic migraine, chronic migraine, retinal migraine, ophthalmoplegic, migraine, acephalgic migraine, migrainous disorder, menstrual migraine, abdominal migraine, childhood periodic syndromes, or cluster headache). Exemplary drugs that may be used in combination with a GLYX peptide include Anafranil, Adapin, Aventyl, Elavil, Norpramin, Pamelor, Pertofrane, Sinequan., Surmontil, Tofranil, Vivactil, Parnate, Nardil, Marplan, Celexa, Lexapro, Luvox, Paxil, Prozac, Zoloft, Welibutrin, Effexor, Remeron, Cymbalta, Desyrel (trazodone), and Ludiomill.
1001071 in certain embodiments, the opioid is selected from the group consisting of alfentanil, butorphanol, buprenoiphine, dextromoramide, dezocine, dextropropoxyphene, codeine, dihydrocodeine, diphenoxylate, etorphine, fentanyl, hydrocodone, hydromorphone, ketobemidorie, loperami d.e, levorphanol, levomethadone, meptazinol, methadone, morphine, morphine-6-g1ucuronide, nalbuphitte, naloxone, oxycodone, oxymowhone, pentazocine, pethidine, piritramide, propoxyphene, remifentanil, sulferitanyl, tilidine, and tram.adol.
[001081 In certain embodiments, the antidepressant is selected from the group consisting of adinazolam, ataproclate, amineptine, amitriptyline/chlordiazepoxide combination, atiparnezole, azainian.serin, bazinaprine, beforatinc, bifeitnelane, binodaline, bipenamol, brofaromine, caroxazorte, cerielamine, cianopramine, cimoxatone, citalopram, clemeprol, clovoxamine, dazepinil, deanol, demexiptiline, dibenzepin, dothiepin, dr oxidopa, enefexine, estazolam, etoperidone, femoxetinc, fengabine, fezolamine, fluo.tracen, ida.zoxan, indalpine, indeloxazine, iprindo1e, levoprofiline, lithium. litoxetine, lofepraTiline, medifoxamine, metapramine, metralindole, rnianserin, milnacipran, minaprine, mirtazapine, montirelin, nebracetarn, nefopam, nialamide, notnifensine, norfluo.xetine, orotirelin, oxaflozane, pinazepain, pirlindole, pizotyline, ritanserin, rolipram, sercloremine, setiptiline, sibutramine, sulbutiamine, sulphide, teniloxazirte, thozalinone, thyroliberin, tianeptine, tiflucarbine, trazodone, tofenacin, tofisopam, toloxatone, tomoxetine, veralipride, viloxazine, viqualine, zimelidine, and zometapine.
[001091 In certain embodiments, the antiepileptic is selected from the group consisting of carbamazepine, flupirtine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, retigabine, topiramate, and vaiproate.
[001101 in certain embodiments, the NSAID is selected from the group consisting of acemetacin, aspirin, cele,coxib, deracoxib, diclofenac, diflunisal, ethenzamide, etofenarnate, etoricoxib, fenoprofen, .flufenainic acid, .flurbiprofen, lonazolac, lornoxicam, ibuprofen, indomethacin, isoxicam, kebuzone, ketoprofen, ketorolac, naproxen, naburnetone, niflurnic acid, sulindac, tolmetin, piroxicam, mec,lofenarnic acid, mefenamic acid, meloxicarn, metamizol, mofebutazone, oxyphenbutazone, parecoxib, phenidone, phertylbutazone, piroxicarn, propacetamol, propyphenazone, rofecoxib, salicylainide, suprofen, tiaprofenic acid, t enox ic am, valdecoxib, 4-(4-cyclohexy1-2-methyloxazol-5-y1)-2 -fl u o rob en zene sulfonami de, N-[2-(cyclohexyloxy)-4-n itr op he n yl] rn e th a ne s ulfo narnide, 2-(3,4-d iflu o ro p h e ny1)-4-( 3 -hydroxy-3 -met hy lb utoxy)-5- [4- ( met 111õ,ls ulfo nyl)r) henyl] -3(2H)-pyrid az inone, and 2-(3,5-di fluor op h e,n.y1)-3- [4- (me thy Is ulfon yl)p e I] -2-cycl op ent en -ne.
[001111 In certain embodiments, the serotonin 5fITIB/ID agonist is selected from the group consisting of eletriptan, frovairiptan, naratriptan, rizatTiptan, s LI
inatriptan, and zoimitriptan.
[0011.21 In certain embodiments, the N-methyl-D-aspartate antagonist is selected from the group consisting of ama.nta.dine, aptiganel, besonprodik budipine, conantokin G, delucemine, dexanabinol, dextromethorphan, dextropropoxyphene, felbamate, fluorofelbamate, gacyclidinc, glycine, ipenoxazone, kaitocephalin, ketamine, ketobemidone, lanicemine, licosiinel, midafotel, -me-mantine, fl-methadone. D-morphine, milnacipran, neramexane, orphenadrine, remacemide, sulfazocine, FPL-12,495 (racemide metabolite), topiramate, (aR)-a-amino-5-chloro-1-(ph o sphonomethyl)- I H-b en zi midazole-2-propanoi c acid, 1 -aminocycl op entane-carbox.ylic acid, [5 -(arn int) me thyl)-2 - [ [ [.(5 S)-9-chl oro-2,3,6,7-te trahydro-2,3-dioxo- 1 H- EI-pyrido [1,2,3 -de] quinoxalin-5-yll a.c etyl] amino] p he noxy ] -acetic acid, a- a mino -2-(2-pho sp hono e thyl)-cycluhexanepropanoic acid, a-amino-4-(phosphonomethyl.)-benzeneacefic acid, (3E)-2-amino-4 -(ph o sp h 0110/11 ethyl)-3 - h eptenoic, acid, 3 - [(iE)-2-earb oxy-2 -p h enyletneri yli -4 ,6-dichloro- 1H-indote-2-carboxylie acid, 8-chloro-2,3-dihydropyridazino14,5-b]quino.1ine-1,4-dione 5-oxide salt with 2-hydroxy-N,N,N-trimethyl-ethanaminium, N '42-chloro-5-(m.ethylthio)phen:µ,71]-N-methyl-N- [3 -(rn eth y ith io )ph eny I] -guanidine, N'42-chloro-5-(methylthio)phertyll -N-methy l-N-[3-[(R)-methylsulfiny1iphenyl]-guanidine, 6-ehloro-2,3,4,9-tetrahydro-9-methyl-2,3-dioxo-1H -indeno[1,2-b]pyrazine-9-acetic acid, 7-chlorothiokynurenic acid, (3S,4aR,6S,8aR)-decahydro-6-(phosphonoMC thyl)-3-isoquinolinecarboxylic acid, (¨)6,7-dichlo ro- 1,4 - d ihydro-5 - [3 -(tri ethoxym eth yl)-5-(3-pyri d iny1)-4- H-1 ,2,4-triazol -4 -2,3 -cin inox alinedione, 4,6-di ehl oro-3 -[(E)-(2-oxo- 1 - p he ny1-3 -pyrrol id inylid ene)methyt] 1H- ind o.le-2 -carboxylic acid, (2R,4 S)-re 5,7 -dich ro - 1,2,3 ,4-tet ra.hydro -4 - apheny kunino)carb onyl] amino.] - 2-citi i no linecarbox.ylic acid, (3R,4 ihydro-344-h ydroxy-4-(phen y ethy1)- 1 -pip eri d iny11-2H- I -benzopyran.-4,7-diol, 2- [(2,3 -dihydro- 1 H- inden-2-yDaminol-acetam ide, 1,4-dihydro-6-methy1-5-V me thy la mino)me thyll -7-nitro-2,3-quinoxalinedione, [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]noa-1(7)-en-2-Aethyl]-phosphonie acid, (2R.,6S)-1,2,3,4,5,6-hexahydro-3-[(2 S)-2-methoxypropy11-6,11 , 11 -tri methy1-2,6-met hano-3 -benzazocin-9-ol., 2-hydroxy-5-[ [(pent afluo rophe ri yprne thyl]am ino] -benzoic acid, 1 -12--(4-hydroxyph enoxy)ethy11-4 - [(4-methylphenyl)me thy I] - 4 -p eridinol, 1-[4 - ( 1H-imida zoi-4 y1)-3 -b Mynyi] -4 -( phe ny lmethyl)-piperidine, 2-triethyl-6-phenylethyny1)-pyridine, 3-(phosphoriomethyl)-L-phenylalanine, and 3,6,7-tetrahy dro-2,3-dioxo-N-p henyl- 111,5 -pyri do [1,2,3 -de] quinoxaline-5-acetamide.
:-30 [001131 la certain embodiments, the anti-inflammatory compound is selected from the group consisting of aspirin, celecoxib, cortisone, deracoxib, diflunisak etoricoxib, ferioprofen, ibuprofen, ketoproferi, riaproxen, prednisolone, sulindac, tolmetin, piroxicam, mefenamie acid, meloxicam, phenylbutazone, rofecoxib, suprofen, valdecoxib, 4-(4-cyclohexy1-2-methyloxazol-5-y1)-2-fluorobenzenesulfonamide, N- [2-(cyclahexyloxy)-4- trophenyl]
methanesu tfon amide, 2-(3,4-di fitioropheny1)-4-(3-hydroxy-3-methy b u tox.y)-5- [4-(methy sulfony Opheny11-3 (2H)-pyri daz ino neõ and 2-(3,5-difluoropheny1)-3- [44 methy s ulfonyl)p heny1]-2-cyclop enten-l-one.
[001141 The disclosure has multiple aspects, illustrated by the following non-limiting Examples.
EXAMPLES
Examolel [001.151 The studies described, herein utilized extracellular multi-site electrophysiological monitoring of SD rate of propagation, and two-pholon laser scanning microscopy for real-time imaging of SD-evoked changes in dendritic spine size, in in vitro hippocampal slices. The effect of a novel NMDAR. receptor functional glycine site partial agonist, GLYX-13 was examined on the threshold and rate of propagation of SD, and real-time effects of SD on dendritic spine mutphology. GLYX-13 occasionally completely prevented the induction of SD
by a local increase in extracellular potassium concentration, and consistently slowed its propagation rate. The passage of SD through the hippocampal CA1 region produced a rapid retraction of dendritic spines which reversed after neuronal depolarization had recovered.
GLYX-13 improved the rate and extent of return of dendritic spines to their original sizes and locations following SD, indicating that the drug and others that modulate NIVIDA receptor activity could protect synaptic connections in the brain from possible damage from repeated migraine attacks.
General Methods Drugs [001161 All external and patch pipette solutions were made with deionized distilled water (resistance > 18 mn cm 2; Milli-Q system), The chemicals for making extra- and intracellular solutions were purchased from Sigma-Aldrich (St. Louis, MO, -USA).
Alex.aFittor 594 was purchased from Molecular Probes.
Slice Preparation and Evil-aceIlular Recordings [001171 Experiments were performed on hippocampal slices from 14 to 21 day old Sprague-Dawley0 rats (Taconic Farms, Hudson, NY). Rats were deeply anaesthetized with isofluorane, sacrificed, and the brains quickly removed and placed in oxygenated (95% 02 5%
CO2), ice-cold artificial cerebrospinal fluid (ACSF) containing (in rnM): 126 NaCl, 2.5 KC1, 2.6 CaC12, 5 1.3 MgC12, 1.25 NaH2PO4, 26 NaHCO3, and 11 Glucose. The brain was hemisected, the frontal lobes cut off, and individual hemispheres glued using cyanoacrylate adhesive to a stage immersed in ice-cold ACSF oxygenated continuously during slicing. 400 um thick coronal slices containing the hippocampas were cut using a -vibratome (Leica 1200s), and transferred to an interface holding chamber for incubation at room temperature for a minimum of I hour 10 before transfer to a Haas-style interface chamber for recording at 32 'C. Slices were perfused with ACSF (4mIlmin; ACSF mM: NaCI 126; KC1 3; NaH2PO4 1.25; MgCI 1.3; CaCl2 2.5;
NaHCO3 26; glucose 10) saturated with 95% 02/5% CO2 prior to start of the experiment, and all drugs were bath-applied.
[001181 Extracellular recordings were carried out using a MultiClamp 700B
(Axon 15 instruments) with Clampex (v. 9), filtered at J. kHz and digitized at 3 kHz. Low resistance (1-2 Mc2 after filled with ACSF) recording electrodes were made from thin-walled borosilicate glass inserted into the apical dendri-tic region of the Schaffer collateral termination field in stratum radiatum of the CA.1 region, at approximately 150 rum distance intervals from the SD initiating pipette, to monitor the spread of S.D. The submerged recording chamber was mounted on a 20 Zeiss Axioskop 2FS upright microscope equipped with infrared differential interference contrast (DIC) optics. A 10x objective was used to image slice luminance change caused by SD. Luminance changes were imaged every 100 ms with a cooled CCD camera (CoolSNAP
HQ) controlled by a PIT master system. Electrophysiological data were analyzed with Clampfit 9. Imaging data were digitized and reconstructed with ImageJ
25 [001.191 A bipolar stainless steel stimulating electrode (PHC, Bowdoin, ME) was placed in Schaffer collateral-commissural fibers in the CA3 region, and current pulses were applied with stimulus intensity adjusted to evoke approximately 50% of maximal fEPSPs once each 30 s (50 to 100 pA; 100 ps duration). Electrical stimulation from an ISO-Flex isolator was controlled by a Master eight-pulse generator (AMPI, Jerusalem, Israel) and triggered by a Multielamp 700B
(Molecular Devices, Sunnyvale, CA). Signals were digitized with a Digidata 1322 and recorded using a Multiclamp 700B amplifier. fEPSP slope was measured by linear interpolation from 20-80% of maximum negative deflection, and slopes confirmed to be stable to within 10% for at least 15 min before commencing an experiment. Data were analyzed using Clampfit (Version 9; Axon Instrument) on an IBM-compatible personal computer. Evoked fEPSPs (50%
of maximum amplitude, 2-4 mV) were recorded in the apical dendritic field in stratum radiatum for a stable baseline period of at least 30 min.
Induction of Hippocampal Spreading Depression [001201 Acute coronal slices of hippocampus were transferred to a submerged recording chamber on a microscope stage and perfused with warmed ACSIF (32 C) where extraeellular [K] was raised to 8 niM at a perfusion rate of 3 mlimin. Spreading depression was initiated by pressure-injecting puffs of 3M KC1 through a glass pipette. Pressure pulses of 8-10 psi that lasted 50-100 ms were driven by a Picospritzer TT (Parker Hannifin, Hollis, NH) Pipette resistances were 2 0.2 Mil when filled with 3 M KO.
Dynamic imaging analysis of dendritic spine retraction/recovery [001211 After loading a CA1 pyramidal neuron in a hippocampal slice with Alexa Fluor 594 (100 1,1\4) for 15 minutes, tertiary dendrites were imaged using a using a customized two-photon. laser-scanning Olympus BX61W1 microscope equipped with a 60x11.1 nA
water immersion infrared objective plus 4x digital zoom, as described previously (Zhang et al., 2008).
XYZ scanning mode in a range of +1- 3 um from focused layer was used to avoid movement bias, with a z step interval of 0.5 um, and each image took 0.45 second to finish, for a single depth profile time of 7 seconds. Great care was taken to avoid both saturation of fluorescence and any signs of phototoxicity to small dendritic spines from too much excitation light. Depth profiles were repeated at 5 min intervals to reduce possible dye photobleaching and phototoxicity. A. .MailTai laser (Solid-State Laser, Mountain View, CA) tuned to 810 nm was used for excitation, and image acquisition controlled by Olympus FluoviewFV300 software (Olympus America, Melville, NY) Epifluorescence was detected with photomultiplier tubes of the confocal laser scan head with pinhole maximally opened and emission spectral window optimized for signal over background. in the rransfluorescence pathway, a 565 nm dichroic mirror was used to separate green and red fluorescence, and passed through HQ525/50 and HQ605150 emission filters, respectively, to eliminate transmitted or reflected excitation light (Chroma Technology, Rockingham, VT), and detected simultaneously by two photomultiplier tubes. The figures show collapsed images from the entire 6 um Z-profile, and these projections were used to calculate intensity as an index of spine volume.
Data Analyses [001.221 Recording signals were filtered through an. eight-pole Bessel low-pass filter with a kHz cutoff frequency and sampled by Clampex (V. 9) with an interval of 100 irs. After fEPSP
slopes were calculated with Clampfit (V.9), the data were further processed with Origin 6.1 (Microcal Software, MA) and presented with CordDraw 10 (Core!, Ottawa, Ontario, Canada).
All data were analyzed by one-way analysis of variance (ANOVA), or Student's t-test using SPSS software (SPSS Inc., Chicago, IL). Significance level was preset to P <
0.05. Data are presented as mean + SEM across experiments.
Results Focal, high [K+j-indueed spreading depression in field CAI of hippocarnpal slices [001231 in artificial cerebrospinal fluid (ACSF) where [1(10 was elevated to 8 niM at 32 'V, a single local puff (100 ms) of 3 M [Kb o onto a field in CA.1 stratum radiatum (Figure 1, top left) reliably induced. SDs which spread at propagation rates of 9 71: 5.4 mm/min (n = 16) over the entire CA1 region of the hippocampus. SD characterized as a negative field potential shift (Figure 1, top right) showed a maximum shift of -8 1.5 niV (n=30) in the stratum radiatum synaptic layer of the hippocampal CA1 region which typically lasted more than 45 seconds.
[001241 SD was induced every 10 minutes to test whether the area of the negative potential shift (Figure 1, top right, hatched area), a measure of the effective magnitude and duration of extracellular space conduction of K.+, was stable with repeated SDs. While the areas of negative potential shifts recorded from the initiating electrode were larger than at the distal recording electrode 600 um away (Figure 1, bottom), there were no significant differences in amplitude or propagation speed of the individual episodes of repeated sequential SDs elicited at 10 minute intervals at either site (Bonferroni Multiple Comparison Test, P> 0.20). These results indicate that reproducible SD negative potential shifts can be stably, repeatedly evoked in field CA.1 of the hippocampus, at least for the first ten.
GLYX-13 suppresses the propagation and increases the refractory period of hippocarnpal spreading depression [001251 To test the hypothesis that the novel NMDA receptor glycine coagonist site partial agonist GLYX-13 could raise the threshold for or prevent SD by regulating NMDA
receptor activation within a physiological range and preventing excess activation, GLYX-13 was bath--applied at 1, 10, or 50 um to hippocampal slices for 30 min prior to brief ejection of high [K+]
(1 miN4 in patch pipette) into stratum radiatum of the CAI region and attempted to elicit SD. A
dose-response relation was constructed based on time of high [K-1-I ejection first in naive slices, and then after a 30 minute bath application of GLYX-13 at each of the three test concentrations (1,10, or 50 M), while recording DC potential to detect SD.
[001261 After at least three SDs were initially evoked in drug-free ACSF, slices were perfused with GLYX-13 and continued to elicit SDs every ten minutes. As illustrated in Figure 2, top, for 10 t.tM GLYX-13, there were no significant differences between the baseline areas of individual sequential episodes of SD at the initiating site (Bonferroni Multiple Comparison Test, P >0.20), indicating that GLYX-13 did not alter the initiation of SD.
[001271 GLYX-13 was next tested to ascertain whether affected the relationship of SD
amplitudes at near (proximal) and far (distal) recording sites with repeated SDs. The slice was perfused with 10 uM GLYX-13 and continued to elicit SDs every ten minutes (Figure 2, bottom). Bonferroni Multiple Comparison Test (P >0.20) again showed no significant difference between the areas of individual sequential episodes of SD in control slices. CiLYX-13 did not affect the initiation of -the negative potential shift of SD at the proximal recording site.
[001281 SD amplitudes at the initiating site were con-elated with areas of negative potential shifts of SD at the remote recording (Figure 2, bottom). Therefore, proximal/distal area ratio in absence and presence of GLYX-13 was compared. As illustrated in Figure 2, bottom, the area ratio between remote and initiating sites was dramatically reduced in the presence of 10 it M
GLYX-13 by the application of the sixth SD (6th SD). A two way ANOVA indicated three significant effects: 1) time effects repeated SDs in the same slices (F(1, 12)=5.17, p <0.05) over all observations; 2) effects from drug treatment (F(1,12)=5.07, p <0.05); and 3) an interaction of time with treatment (F(1,12)=30.91, p <0.01). These results indicate that recurrent negative potential shifts of SD alter the amplitude ratio between remote and initiating sites; and that this reduction was markedly enhanced by GLYX-13. These findings show that GLYX-13 can significantly suppress the propagation of SD through the brain, particularly after multiple SD
events.
[001291 In the preceding studies, it was demonstrated that GLYX-13 can limit the propagation of SD by reducing the amplitude of the negative field potential shift and slowing the conduction speed, effects that were largest after multiple SDs. By shortening the interval between each SD initiation, it was discovered that each SD in control slices had an absolute refractory period of 3-4 minutes for the next successful SD = 7).
10 1,t1\4 GLYX-13 prolonged this refractory period to 5-6 minutes (n = 6). A.s shown in Figure 3, SD could be successfully evoked five minutes after a previous SD in a control slice (Control), but could not be elicited in a slice treated with GUYX-13 (GUY-X-13 30').
Measuring SD propagation using intrinsic changes in optical density produced by SD-induced extracellular space volume shifts [001301 SD elicits profound shrinkage of the extracellular space volume as fluid rushes in to depolarized cells and they swell, and this can. be seen as changes in intrinsic optical density in vivo. Such luminance intensity changes could also be readily detected in brain slices using transmitted light DIC microscopy. Figure 4A shows that an SD "aura" of increased luminance spreads from the initiating pipette and propagates across the slice, and can be used to calculate SD conduction velocity (Figure 4B). The time course of increased luminance correlated well with maximal negative potential shift of SD using electrophysiological recordings. Therefore, calculating the time course of luminance changes with distance provides an accurate and convenient way to measure SD conduction velocity.
[001.311 To determine if repeated SDs show the same conduction velocity, the luminance changes were monitored over 5 points separated by 150 um as diagrammed at the top of Figure 4A. A one way ANOVA with repeated measures indicated that SD maintained a steady transmitting speed from P1 to P5 (F(5, 35)=2.42, p >0.05) within an individual slice. Therefore, the transmitting speed could be used from PI to P5 to test SD stability over successive episodes. The average propagating speed of SD was 9.07 0.55 inn 'mm, ranging from 7,54 to 11.14 mm/mmn (n=16).
[001321 To test whether repeated episodes of SD maintained a stable speed and if GLYX-13 affected SD conduction velocity, a ANOVA test was used with repeated measures to analyze 6 subsequent SDs as illustrated in Figure 5. Analysis revealed a significant difference between control and GLYX-13 treated slices (F(1,50)=3.66, p <0.01). SD sequence accounted for 38.5%
of total variance, indicating that SD propagation speed significantly slowed with increasing SD
number (F(5,50)=14.01, p <0.01). Although the GLYX-13 effect on SD propagation speed 5 over all repeated SDs did not reach significance in the two-way ANOVA, there was a significant interaction between number of SD and GLYX-13 treatment (F(5,50)=2.53, P
<0.05), reflecting that GLYX-1 3 (filled circles) significantly decreased SD
propagation speed only by the seventh SD.
Spreading depression causes CA1 pyramidal neuron dendritic spines to reversibly shrink in volume [001331 The anatomical microarchitecture of pyramidal neuron dendrites in the brain is 1.0 surprisingly labile in response to a variety of stimuli.
Depolarization, oxygen/glucose deprivation and N-methyl-D-aspartate have all been shown to produce retraction of dendritic spines in hippocampal CA1 pyramidal neurons in vitro. To examine the response of spines to SD, single CA1 pyramidal neurons were filled with the fluorescent dye Alexafluor-594 and imaged dendritic spine shape using serial z-stack sections (0.2 urn steps spanning 5 lim) 15 collected from 2-photon laser scanning microscopy. Thirty minutes after loading of Alex.aFluror-594 into CAI pyramidal had reached equilibrium distribution within the neuron, SDs were initiated by brief ejection of high [K+] (1M in the patch pipette) into stratum radiatum of the CA1 region of hippocampal slices where Schaffer collateral axons synapse on the apical dendrites of CAI pyramidal neurons. As illustrated in Figure 6A and 6B, the 20 depolarization produced by SD did elicit substantial spine shrinkage as measured by collapsed z-stack fluorescence amplitude, with spine volume completely recovering 20-30 minutes after the first SD. This confirms that one of the sequelae of SD-induced depolarization is alteration in dendritic spine morphology.
GLYX-13 improves dendritic spine recovery following spreading depression [001341 Finally, the effects of GLYX-13 were examined on the dynamic morphological 25 responses of dendritic spines to SDs. GLYX-13 was investigated whether it could either lessen the shrinkage of spines in response to SD, or improve their recovery. Figure 6A illustrates spine shrinkage in response to two episodes of SD in a control pyramidal neuron, while Figure 6B
exemplifies the same process in the presence of 10 m.1%.1 GLYX-13. ANOVA. for repeated measures reached significance (F(8,64)=17.53, p<0.001) for fluorescent intensity measured from dendritic spines like the one illustrated at the top of Figure 6C, and that this significance mainly came from the post-SD time courses (F(8,64)=6,18, p<0.01), revealing that, while GLYX-13 (filled circles) did not alter the shrinkage caused by SD, it did rescue the recovery of spine size following SD (F(8,64)=2.81, p<0.05).
Example 2 [00135] Hippocampal Slice Preparation: Experiments were performed using Sprague-Dawley0 rats (Taconic Farms) .14 to 21 days of age. Rats were deeply anaesthetized with isofluorane, sacrificed, and the brains quickly removed and placed in oxygenated (95% 02 ---5% CO2), iced-cold artificial cerebrospinal fluid (ACSF) containing (in miv1):
126 NaC1, 2.5 KCl, 2.6 CaC12, 1.3 MgC12, 1.25 Na.H2PO4, 26 NaHCO3, and 11 Glucose. The brain was hemisected., the frontal lobes cut off, and individual hemispheres glued using cyanoacrylate adhesive to a stage immersed in ice-cold ACSF oxygenated continuously during slicing. 400m thick coronal slices containing the hippocampus were cut using a Vibratome (Leica. I200s), and transferred to an interface holding chamber for incubation at room temperature for a minimum of 1 hour before commencing the experiment.
[001361 induction of Hippocampal Spreading Depression: Acute corona! slices of hippocampus were transferred to a submerged recording chamber on a microscope stage and perfused with warmed ACSF (32 degree centigrade) where extracellular [K+1 was raised to 8 inM at a perfusion rate of 3 milmin. Spreading depression was initiated by pressure-injecting puffs of 3M l(C1 through a glass pipette. Pressure pulses of 8-10 psi that usually lasted 50 ms were driven by a picospritzer. Pipette resistances were 2 0.2 Mn when filled with 3 M KO.
[001371 Electrophysiological. Recording Methods: Extracellular recordings were carried out using a MultiClamp 70013 (Axon Instruments) with Clampex (v. 9), filtered at 1 kHz and digitized at 3 kHz. Low resistance (1-2 MO. after filled with ACM recording electrodes were made from thin-walled borosilicate glass inserted into the apical dendritic region of the Schaffer collateral termination field in stratum radiatum of the C,A.1 region, at approximately 150 mm distance intervals from the SD initiating pipette, to monitor the spread of SD. The submerged recording chamber was mounted on a Zeiss A.xioskop 2FS upright microscope equipped with infrared differential interference contrast (DIC) optics. A 10x objective was used to image slice luminance change caused by SD. Luminance changes were imaged every 100 ms with a cooled CCD camera (CoolSNAP HQ) controlled by a PTI -master system.
Electrophysiological data were analyzed with Cla.mpfit 9. Imaging data were digitized and reconstructed with imageJ (NTH). All experiments were conducted under an approved protocol in compliance with National Institutes of Health guidelines [001381 The findings of Example I are investigated relating to women and adolescent patients. The experimental protocol was used to initiate spreading depolarization (Si)) in the CA1 region of the hippocampus inbrain slices in vitro. To better observe the distance of spreading depression from the initiation site and SD propagation speed over a longer range visually, the 1.0x objective of Example 1 was replaced with a 4x objective to enlarge the viewing domain to 1.6 mm. The recording chamber was modified to perfuse the slice from both sides, more efficient perfusion not only provided sufficient oxygen to the brain slice, but also helped to maintain stable extracellular milieu since each episode of spreading depression causes a dramatic ion composition change both extracellularly and intracellularlly.
[001391 Two groups of 2 month-old, uvariectomized Sprague-Dawley female rats were included in the current cohort study. One group of ovariectornized rats were provided with daily injections of estrogen for 7 days since the 7th post-operation day, while the others were only injected with oil vehicle as controls for 7 days before conducting experiments.
[001401 The luminance changes were visually categorized following a puff of 3 M
potassium as failure (<100 mm), local spreading (>100.mm; <800 mm); or full spread (>800 mm). SD induction was attempted in 39 slices from 8 oil--treated rats and 35 slices from 7 estrogen-treated rats. Table I summarizes the frequency of occurrence of SD
evoked by the same method in the two groups. in the oil-treated group, the failure rate was significantly higher than in the estrogen treated group (Chisquare test, P-0.014), indicating that estrogen itself enhances the propensity of brain tissue to exhibit SD upon focal depolarization.
Table 1 Group Non-SD Localized SD -Full SD Total Oil Treated 13 21 5 39 Estrogen Treated 6 23 6 35 [001411 Luminance changes were used to estimate the transmitting velocity of spreading depression as shown in Figure 7 below. Propagation velocities were calculated from both localized and full SD induced by focal 31M. potassium puffs, by dividing the distance of SD
between observation sites by time that SD took to travel between these observation sites. As illustrated in Figure 7, mean spreading speed in slices from estrogen-treated rats was 0.121+
0.013 minis, significantly faster than the speed of propagation in slices from of oil-treated control rats (0.083 0.005 mm/s, P<0.05, Student's t-test. These data indicate that estrogen plays a significant role in enhancing both the propensity and speed of SD in hippocampus, and probably in neocortex as well.
in [001421 Testing of how estrogen affects the severity of SD by measuring the maximum distance of propagation of SD away from the initiation site was conducted. As shown in Fig 8, the spreading end point along the Schaffer collateral pathway estimated by averaging the distance of the observation site that showed minimum detectable luminance changes (>5%
change from baseline) from the initiation site with the distance of the close neighboring observation site that exhibited undetectable luminance changes, and measuring this distance from the initiation site. As shown in Figure 8, the SD in slices from estrogen-treated rats traveled a significantly longer distance (0.594 0.071 mm; n=18) than SD in slices from oil-treated rats (0.394 + 0.051.mm; n=16, P<0.05, Student's t-test). Hence, SD in estrogen-treated rats was not only more readily elicited, but propagated longer distances.
00143[1 10 11\4. GLYX-13 was then added to the perfusate after 2 &is were induced 10 minutes apart, and continued to induce SD each 10 minutes to determine whether the velocity and scale of SD were affected. Figure 9 shows the typical differences of evoked SD in a slice from an estrogen-treated rat before application of GLYX-13 and after a 50 minute exposure to 10 1,1\4 bath-applied GLYX-13. The luminance changes at 10 observation sites were measured to assess the effects of GLYX-13 on SD. Although SD was still readily evoked, as shown in Figure 9B, Figure 9A clearly shows that luminance changes associated with SD
were delayed in the presence of GLYX-13. A. paired t-test showed that GLYX-13 significantly reduced mean SD transmission velocity from 6.56 0.57 mm/min to 4.96 0.28 mm/min (n=5, P<0.01, paired nest). The same experiments in hippocampal slices from oil-treated rats were conducted.
3 0 While GLYX-13 decreased mean SD transmission velocity from 5.09 0.61 min/min to 4.50 +
0.39 nunlinin (n=5), this decrease did not reach statistical significance.
[001441 A two-way repeated ANOVA was also carried out to explore the effect of GLYX-13 on SD propagation speed across the two groups. As Figure 10 illustrates, the first significance comes from estrogen treated rats before and after application of (F(1,8)=3.1;p<0.05); and the second significance arises from preexposure of between the two groups (F(1,8)=4.2; p<0.05). These results indicate that GLYX-13 has a stronger effect in estrogen treated rats, significantly slowing transmission velocity of SD to the level of oil-treated rats.
Example 3 Methods Animals [001451 Adult male (2-3 month old) Sprague-Dawley (SD) rats were purchased from Harlan (USA). Rats were housed in Lucite cages with aspen wood chip bedding, maintained on a 12 hour:12. hour light:dark cycle (lights on at 5 AM), and given ad libitum access to Purina rat chow (USA) and tap water throughout the study.
Traumatic brain ii-ijury induction [001461 Single blast-induced traumatic brain injury was induced, modified for use in rats according to the protocol of Goldstein et al. (Goldstein, LE, et al. (2012) "Chronic traumatic encephalopathy in blast-exposed military veterans and a blast neuratrauma mouse model,"
Science Translational Medicine 4:134ra160.) Adult male Sprague-Dawley rats were anesthetized by isofturane, ear plugs were inserted into both of the rat's ears, and the rat received a single ¨ 42 PSI blast of helium generated by puncturing, 0.014 inches of polyester films Sham controls were placed outside of the blast radius. As follows Animals were dosed with rapastinel (3 mg/kg IV) or 0.9% sterile saline vehicle (1 milkg IV) 1 hour post-blast Rats were first anesthetized using 3.5-4% isoflurane, then their ears were protected with 1.5 x 1.5 mm foam plugs (Pura-Fit ear plugs, Moldex-Metric INC, Culver City, California). The rats were placed into head access rodent thoracic restrainers (Stoelting, USA) to protect their bodies while allowing the heads to move freely, with the heads 10 cm from the end of the aluminum shock tubes (183 x 61 cm; L-3 Applied Technologies, USA). Rats received a single ¨42 PSI
blast of helium generated by puncturing 0.014 inches of polyester film. Sham controls were placed outside of the blast radius. Animals were dosed with rapastinel (3 mg/k2 IV) or 0.9%
sterile saline vehicle (1 mIlkg, IV) 1 hour post-blast. Latency to recover from anesthesia was recorded (Figure 11A). Recovery was defined as displaying eyeblink and righting reflexes, and normal ambulation (normal rhythmic gate, non-circular gate, fully supporting body weight, evidence of some sniffing and exploratory behaviors). Animals were dosed with GLYX-13 (3 5 mg/kg IV) or 0.9P/0 sterile saline vehicle (1 mUkg IV) 1 hour post-blast.
N ¨ 4-6 per group; * P
<0.05 (Figure 11A) ANOVA..
1001471 Positive emotional learning (PEL) Figure 11B shows the results of a single 3 min Positive Emotional Learning (PEL) test session conducted 24 hours post-blast using a between subjects design. N -= 4-6 per group. Fisher's PLSD post hoc test was used to evaluate results 10 (rapastinel TBI vs. vehicle -H TBI).
1001481 Heterospecific rough-and-tumble play was conducted as previously described (Burgdorf, J., et al. (20.11) "Positive emotional learning is regulated in the medial prefrontal cortex by G1uN2B-containing NMDA receptors," Neuroscience 192:515-523), and testing occurred 3 hours and 2 weeks post-dosing. Heterospecifie rough-and-tumble play stimulation 15 was administered by the experimenter's right hand. Animals received 3 mm of 1-3eterospecific rough-and-tumble play that consisted of alternating 15 sec blocks of heterospec,ific play and 15 sec of non-stimulation. High frequency ultrasonic vocalizations (USVs) were recorded and analyzed by sonogram with Avasoft SA.Slab Pro (Germany) as previously described (Id.).
Frequency modulated 50-kHz USVs that occurred during each of the non-stimulation periods 20 were quantified to measure PEL. Animals were not habituated to play stimulation before testing.
Results 1001491 As shown. in Figure 11A, animals that received TBI showed longer recovery times from anesthesia in comparison to sham control animals 13) = 4L7 , P < 0.05]. As shown in Figure 11B, rapastinel (3 mg/kg IV) rescued TBI-induced suppression of positive emotional 25 learning [F(2, 12) ¨ 10.0, P < .05; Fisher's PLSD post hoc test rapastinel TBI vs. vehicle sham vs. vehicle Tat vs., P <0.05]. In addition, anesthesia recovery time was not significantly correlated with rates of PEI., [r(15) = -0.14, P > .05]. in a positive emotional learning test, a single dose of rapastinel (3 mg/kg IV) completely rescued the deficits in learning and emotion induced by TBI. Thus, in this preclinicat niodel, rapastinel was effective in treating the core cognitive and affective symptoms of TBI and rapastinel appears the have therapeutic potential for the treatment of PTSD.
EQUIVALENTS
[001501 While specific embodiments of the subject disclosure have been discussed, the above specification is illustrative and not restrictive. Many variations of the disclosure will become apparent to those skilled in the art upon review of this specification.
The full scope of the disclosure should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with. such variations.
[001511 Unless otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, parameters, descriptive features and so forth used in the specification and claims are to be understood as 'being modified in all instances by the term "about"
Accordingly, unless indicated to the contrary, the numerical parameters set forth in this specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the disclosure.
[001521 All publications and patents mentioned herein, including those items listed below, are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference.
in case of conflict, the present application, including any definitions herein, will control.
10031] Migraine with aura, or "classic migraine", usually involves migraine headaches accompanied by an aura. Less commonly, an aura can occur without a headache, or with a nonmigraine headache. Two other varieties are familial hemiplegic migraine and sporadic hemiplegic migraine, in which a person has migraines with aura and with accompanying motor weakness. if a close relative has had the same condition, it is called "familial", otherwise it is called "sporadic". Another variety is basilar-type migraine, where a headache and aura are accompanied by difficulty speaking, world spinning, ringing in. ears, or a number of other brainstem-related symptoms, but not motor weakness. This type was initially believed to be due to spasms of the basilar artery, the artery that supplies the brains-tem.
Guidelines for diagnosis of migraine with aura are found, for example, in Eriksen. et al., European Journal of Neurology 11 :583-591, 2004 and in the international Classification of Headache Disorders, Second Edition KHD-H). Subtypes of migraine with aura include those set forth in the IdHD-ii such as typical aura with migraine headache (1HS 1.2.1), typical aura with non-migraine headache (THS 1.2.2), typical aura without headache OHS 1.2.3), familial hemiplegic migraine (IRS
1.2.4), sporadic hemiplegic migraine OHS 1.2.5), and basilar-type migraine (fliS 1.2.6).
[00321 Childhood periodic syndromes that are commonly precursors of migraine include cyclical vomiting (occasional intense periods of vomiting), abdominal migraine (abdominal pain, usually accompanied by nausea), and benign paroxysmal vertigo of childhood (occasional attacks of vertigo).
100331 Retinal migraine involves migraine headaches accompanied by visual disturbances or even temporary blindness in one eye.
[00341 Complications of migraine describe migraine headaches and/or auras that are unusually long or unusually frequent, or associated with a seizure or brain lesion.
100351 Probable migraine describes conditions that have some characteristics of migraines, but where there is not enough evidence to diagnose it as a migraine with certainty (in the presence of concurrent medication overuse).
[00361 Chronic migraine is a complication of migraines, and is a headache that fulfills diagnostic criteria for migraine headache and occurs for a greater time interval. Specifically, greater or equal to 15 days/month for longer than 3 months.
[0037] There are four possible phases to a migraine, although not all the phases are necessarily experienced: (1) The prodrome, which occurs hours or days before the headache;
(2) The aura, which immediately precedes the headache; (3) The pain phase, also known as headache phase; and (4) The postdrome, the effects experienced following the end of a migraine attack.
[0038] Prodromal or premonitory symptoms occur in ¨60% of those with migraines with an onset of two hours to two days before the start of pain or the aura. These symptoms may include a wide variety of phenomena including: altered mood, irritability, depression or euphoria, fatigue, craving for certain food, stiff muscles (especially in the neck), constipation or diarrhea, and sensitivity to smells or noise. This may occur in those with either migraine with aura or migraine without aura.
[00391 An aura is a transient focal neurological phenomenon that occurs before or during the headache. They appear gradually over a number of minutes and generally last fewer than 60 minutes. Symptoms can be visual, sensory or motor in nature and many people experience more than one. Visual effects OCCUr most frequently; they occur in up to 99?/o of cases and in more than 50% of cases are not accompanied by sensory or motor effects. Vision disturbances often consist of a scintillating scotoma (an area of partial alteration in the field of vision which flickers and may interfere with a person's ability to read or drive.) These typically start near the center of vision and then spread out to the sides with zigzagging lines which have been described as looking like fortifications or walls of a castle. Usually the lines are in black and white but some people also see colored lines. Some people lose part of their field of vision (known as hemianopsia) while others experience blurring.
[00401 Sensory aurae are the second most common type; they occur in 30-40% of people with auras. Often a feeling of pins-and-needles begins on one side in the hand and arm and spreads to the nose-mouth area on the same side. Numbness usually occurs after the tingling has passed with a loss of position sense. Other symptoms of the aura phase can include: speech or language disturbances, world spinning, and less commonly motor problems Motor symptoms indicate that this is a hemiplegic migraine, and weakness often lasts longer than one hour unlike other auras.
[0041] An aura may also occur without a subsequent headache. Acephalgic migraines, also known as silent migraines, are relatively rare and include an aura and other symptoms but without a subsequent headache (i.e., no pain phase).
[00421 During the pain phase, the headache usually is unilateral, throbbing, and moderate to severe in intensity. It usually com.es on gradually and is aggravated by physical activity. In more than 40% of cases however the pain may be bilateral, and neck pain is commonly associated. Bilateral pain is particularly common in those who have migTaines .without an aura.
Less commonly pain may occur primarily in the back of top of the head. The pain usually lasts 4 to 72 hours in adults, however in young children frequently lasts less than 1 hour. The frequency of attacks is variable, from a few in a lifetime to several a week, with the average being about one a month.
[00431 The pain is frequently accompanied by nausea, vomiting, sensitivity to light, sensitivity to sound, sensitivity to smells, fatigue and irritability. in a basilar migraine, a migraine with neurological symptoms related to the brain stem or with neurological symptoms on both sides of the body, common effects include: a sense of the world spinning, light-headedness, and confusion. Nausea occurs in almost 90% of people, and vomiting occurs in about one-third. Other symptoms may include: blurred vision, nasal stuffiness, diarrhea, frequent urination, pallor, or sweating. Swelling or tenderness of the scalp ma:yr occur as can neck stiffness.
[0044] The effects of migraine may persist for some days after the main headache has ended; this is called the migraine postdrome. Many report a sore feeling in the area where the migraine was, and some report impaired thinking for a few days after the headache has passed.
The patient may feel tired and have head pain, cognitive difficulties, gastrointestinal symptoms, mood changes, and weakness.
GLYX Peptides [0045] GLYX-l3 is a newly-developed rapid-acting, long-lasting antidepressant with unprecedented modulatory actions on the activation of N-methyl-D-aspartate glutamate receptors (NMDAR). This agent, which acts at the obligatory co-agonist glycine site on the NA/IDA receptor required for it to be activated, normalizes activation of this critical receptor, increasing it when it is too low, and suppressing it when it is too high.
Through this action, GLYX-13 can enhance the induction of long-term potentiation (LTP), while suppressing LTD, of synaptic strength, and restore normal LTP in hippocampal slices from aging animals.
[00461 As used :herein, the term "GLYX peptide" refers to a peptide having NMDAR
glycine-site partial agonistlantagonist activity. GLYX peptides may be obtained by well-known recombinant or synthetic methods such as those described in US Patents 5,763,393 and 4,086,196 herein incoiporated by reference. In some embodiments, GLYX refers to a tetrape tide having the amino acid sequence Thr-Pro-Pro-Thr, or L-threonyl-L-prolyl-L-prolyl-1.0 L-threonine amide.
l00471 For example, GLYX-13 refers to the compound depicted as:
= oo, 0 H
H 2N ,kk N N H 2 N N
H
Formula I
[00481 Also contemplated are polymorpbs, homologs, hydrates, solvates, free bases, and/or suitable salt forms of GLYX-13 such as, but not limited to, the acetate salt.
The peptide may be cyclized or non-cyclized form as further described in US 5,763,393. In some embodiments, an a GLYX-13 analog may include an insertion or deletion of a moiety on one or more of the Tin or Pro groups such as a deletion of CH2, OH, or NI712 moiety. in other embodiments, GLYX-13 may be optionally substituted with one or more halogens, CI-C3 alkyl (optionally substituted with halogen or amino), hydroxyl, andior amino. Glycine-site partial agonist of the NMDAR
are disclosed in US 5,763,393, US 6,107,271, and Wood et al., NeuroReport, 19, 1059-1061, 2008, the entire contents of which are herein incorporated by reference.
l00491 It may be understood that the peptides disclosed here can include both natural and unnatural amino acids, e.g., all natural amino acids (or derivatives thereof), all unnatural amino acids or derivatives thereof), or a mixture of natural and unnatural amino acids. For example, one, two, -three or more of the amino acids in GLYX-13 may each have, independently, a D- or -L-configurati on.
[0050] GLYX-13 may act predominantly at NR2B-contairting NMDARs, and may not display the classic side effects of known NMDAR modulators such as CPC-101,606 and 5 ketamine in certain embodiments, an anti-migraine or other therapeutic effect with essentially no sedation may be produced by GLYX- I 3 when administered to a subject in therapeutically effective amounts. In still other embodiments, CiLYX-13 may not have abuse potential (e.g., may not be habit-forming).
[0051] In some embodiments, GLYX-13 may increase AMPA GluRl serine-845 10 phosphorylation. In certain embodiments, glycogen synthase kinase 3 (GSK-30) may be activated by GLYX-13. In some cases, levels of 13-catenin may be altered after administration of GLYX-13.
[00521 In some embodiments, GLYX-13 or a composition comprising GLYX-13 may provide better i.v. in vivo potency and/or brain level concentration, relative to plasma levels.
[0053] Additionally, GLYX-13 may have a wide therapeutic index compared to glycine site antagonists such as L-701,324, or other gl:,,,cine site antagonists having narrow therapeutic indexes, which result in a very narrow range of dose between therapeutic effects and ataxia. For example, L-701,324 had anticonvulsant effects at doses that produced ataxia (Bristow, et al.
PET 279:492-501, 1996). Similarly, a series of Wierz compounds had anticonvuisant effects at doses that produced ataxia (Parsons, et al., JPET283:1264-1275, 1997).
Methods [00541 in one aspect, the invention relates to a method for treating migraine in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound represented by:
0 y NC:
'OH
or pharmaceutically acceptable salt thereof i [00551 In certain embodiments, the compound is administered to the patient with a dose of about 0.01 inivikg to about 1000 mg/kg or about 1 mg/kg to about 500 mg/kg of the compound.
10056] In certain embodiments, the migraine is episodic migraine, chronic migraine, retinal migraine, ophthahnoplegic migraine, acephalgic migraine, migrainous disorder, menstrual migraine, abdominal migraine, childhood periodic syndromes, or cluster headache.
[00571 In certain embodiments, the migraine is episodic migraine, chronic migraine, retinal migraine, oplithalnroplegic migraine, acephalgic migraine, or cluster headache.
10058[ In certain embodiments, the migraine is migraine with aura (classical migraine.).
[0059j in certain embodiments, the migraine is migraine without aura (common migraine.).
[00601 In certain embodiments, the migraine is accompanied by allodynia.
[00611 In certain embodiments, the method comprises administering about I
to 10 mg/kg, about 10 mg/kg to about 250 mg/kg, about 20 mg/kg to about 150 mg/kg, about 30 mg/kg to about 125 mg/kg, about 40 -mg/kg to about 110 mg/kg, about 50 mg/kg to about 100 mg/kg, about 60 mg/kg to about 90 mg/kg, or about 70 mg/kg to about 90 mg/kg, of the compound.
[00621 In certain embodiments, the method comprises administering about 1 mg/kg, about 2.5 mg/kg, about 5 mg/kg, about 10 mg/kg, about 15 -mg/kg, about 20 mg/kg, about 25 -mg/kg, about 30 mg/kg, about 50 mg/kg, about 70 mg/kg, or about 100 mg/kg of the compound.
10063] In certain embodiments, the method comprises administering the compound about twice a day, about every day, every 2 days, every 3 days, every 4 days, every 5 days, about once a week, about every two weeks, or about every four weeks.
[00641 In another aspect, the invention relates to a method of treating, suppressing, Of preventing cortical spreading depression or a disease or condition caused by cortical spreading depression in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound represented by:
OH
`eõ..
Li NH 2 'OH
or pharmaceutically acceptable salt thereof.
[00651 In another aspect, the invention relates to a method of treating Of ameliorating long-term post migraine sequel.ac in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound represented by:
H
'Nts H2Nh-N,It's `^"OH
or pharmaceutically acceptable salt thereof [0066] in certain embodiments, the compound is administered to the patient with a dose of about 0.01 ing/k.g to about 1000 mg/kg of the compound. In certain embodiments, the compound is administered to the patient with a dose of about 1 mg/kg to about 500 mg/kg of the compound.
[00671 In certain embodiments, the method comprises administering about 1 mg/kg to 10 -mg/kg, about 1 mg/kg to 20 mg/kg; about 10 mg/kg to about 250 mg/kg, about 20 mg/kg to about 150 mg/kg, about 30 mg/kg to about 125 mg/kg, about 40 mg/kg to about 110 mg/kg, about 50 mg/kg to about 100 mg/kg, about 60 mg/kg to about 90 mg/kg, or about 70 mg/kg to about 90 mg/kg, of the compound.
l00681 In certain embodiments, the method comprises administering about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 50 mg/kg, about 70 mg/kg, 1 mg/kg, 5 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg or about 100 mg/kg of the compound.
[00691 In certain embodiments, the method comprises administering the compound about twice a day, about every day, every 2 days, every 3 days, every 4 days, every 5 days, about once a week, or about every two weeks, or e.g., every month.
[00701 In certain embodiments, the method further comprises co-administration with an opioid, an antidepressant, an antiepileptic, a non-steroidal anti-inflammatory drug (NSAID), a serutonin 5E1T IB/1D agonist, an N-methyl-D-aspartate antagonist, or an anti-inflammatory compound.
[00711 NMDAR activation may promote or even be essential for, the phenomenon of SD in many experimental situations. Therefore, compounds that prevent over-activation of NNIDARs could be important new therapies for lessening, and even preventing, the onset of migraine attacks. For example, CiLYX-13, discussed below, suppresses the production and propagation of SD in hippocampal slices in vitro. In certain experiments, GLYX-13 may completely prevent the induction of SD by local increase in extracellular potassium concentration, and/or if not blocking it completely, may slow the rate of SD propagation. Furthermore, CILYX-13 can improve the return of dendritic spines to their original sizes following an SD. For example, provided herein are methods of treating migraine in patients prophylacticly and/or on an acute basis. Such administration may ameliorate the severity (or in some embodiments, abort) migraine attacks in patients.
[00721 In certain embodiments, the patient is a human. Contemplated patients include female patients and/or adolescent patients.
[00731 Also provided herein arc methods of treating migraine (e.g., episodic migraine, chronic migraine, retinal migraine, ophthalmoplegic migraine, acephalgic migraine, migrainous disorder, menstrual migraine, abdominal migraine, childhood periodic syndromes, or cluster headache) in neatment-resistant patients or treating refractory migraines, e.g., patients suffering from a migraine that does not, andlor has not, responded to adequate courses of at least one, or at least two, other compounds or therapeutics. For example, provided herein is a method of treating migraine (e.g., episodic migraine, chronic migraine, retinal migraine, ophthalmoplegic migraine, acephalgic migraine, migrainous disorder, menstrual migraine, abdominal migraine, childhood periodic syndromes, or cluster headache) in a treatment resistant patient, comprising a) optionally identifying the patient as treatment resistant and b) administering an effective dose of GLYX-13 to said patient. In certain embodiments, the migraine is migraine with aura.
[00741 Provided herein, in an embodiment, are methods of acutely treating migraine (e.g., episodic migraine, chronic migraine, retinal migraine, ophthalmoplegic migraine, acephalgic migraine, migrainous disorder, menstrual migraine, abdominal migraine, childhood periodic syndromes, or cluster headache) in a patient in need thereof, comprising administering an effective amount of a GLYX peptide, for example, in a single unit dose. For example, contemplated herein in an embodiment, is a method of treating migraine in a patient in need thereof at the onset of a migraine attack comprising administering acutely (e.g., a single dose) an effective amount of GLYX-13. Such methods may relieve the patient of at least one symptom of migraine for about 2 weeks or less, 1 week or less, 1 day or less, or 1 hour or less (e.g. 15 minutes or less, half an hour or less), after said administration. In some embodiments, such methods may relieve the patient of at least one symptom of migraine for about 1 day or more, I week or more, or 2 weeks or more after said administration. For example, provided herein is a method comprising administering an. effective amount of a GLYX
peptide to a patient suffering from migraine, wherein said patient is substantially relieved of at least one symptom of migraine substantially earlier after the first administration of a GLYX peptide, as compared to the same patient administered another medicament for heating migraine. One of skill in the art will appreciate that such methods of acute administration may be advantageous in a hospital or oat-patient setting. The methods described herein can also be useful for the treatment of allodynia that occurs during migraine with aura.
[0075] The present methods may also be used in treatment of patients who have depression, suffer from traumatic brain injury, epilepsy, or are at risk of a stroke. For example, provided herein, in an. embodiment, is a method for treating traumatic brain, injury comprising administering an effective amount of a GLYX peptide, e.g., GLYX-13. In another embodiment, a method for treating epilepsy is provided, comprising administering an effective amount of a GLYX peptide, e.g., GLYX-13.
[0761 In addition to cardiovascular conditions, migraine sufferers with aura may be at increased risk for other neurological and/or psychological conditions and disorders. it has been shown., for example, that the co-occurrence of migraine with aura with major depression or a suicide attempt increased the risk of developing unprovoked seizure (Hesdorffer et al., Epilepsy Res. 75(2-3):220-223, 2007). Other conditions associated with migraine with aura include significantly higher markers of NO activity, increased incidence of depression, and genetic biomarker correlation for stroke substantially greater than that of the general population (Etminan et al., ttiv1J330(7482):63, 2005). A migraine sufferer that has, or is at risk of, any of these conditions may take medications to treat or to manage these diseases, and these medications may adversely interact with currently used medications for the treatment of migraine with aura. As shown herein, some of these conditions are contraindications for triptan therapy (e.g., stroke and sumatriptan therapy). Moreover, the FDA issued a public health advisory in 2006 regarding serotonin syndrome, a life-threatening condition that may occur when. a tripta.n is used together with certain anti-depressants that are serotonin reuptake inhibitors (SSR1s) or selective serotonin/norepinephrine reuptake inhibitors (SNRIs).
Accordingly, the methods described herein may be useful for the -treatment of patients who have depression or patients who have suffered, or are at risk of, stroke.
Dosages [00771 The dosage of any compositions of the disclosure will vary depending on the symptoms, age and body weight of the patient, the nature and severity of the disorder to be 5 treated or prevented, the route of administration, and the form of the subject composition. Any of the subject formulations may be administered in a single dose or in divided doses. Dosages for the compositions of the disclosure may be readily determined by techniques known to those of skill in the art or as taught herein. In general, satisfactory results can be obtained when the compound is administered to a human at a daily dosage of, for example, between 0.05 mg and 10 3000 mg (measured as the solid form), e.g. about 10 mg to about 500 mg, or e.g., about 1 to about 200mg/kg. Dose ranges include, for example, between 10-1000 mg (e.g., 50-800 mg). In some embodiments, 50, 100, 150, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, or 1000 mg of the compound is administered.
Alternatively, the dosage amount can be calculated using the body weight of the patient. For example, the dose of is a compound, or pharmaceutical composition thereof, administered to a patient may range from 1-500 mg/kg (e.g., 5-250 mg/kg). In exemplary, non-limiting embodiments, the dose may range from 5-200 mg/kg (e.g., 1, 2, 2.5, 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 mg/kg) or from 15-100 mg/kg (e.g., 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200 mg/kg). In exemplary, non-limiting embodiments, the dose may range from 1-15 mg/kg, 50-100 .mg/kg, 60-90 mg/kg, or 70-80 mg/kg.
[00781 GLYX-13 may provide a high therapeutic index. For example, GLYX-13 may be therapeutically effective with an i.v. or subcutaneous dose range of about 1 to about 10 mg/kg, about 10 to about 200 mg/kg, e.g. about 30 mg/kg, about 75 mg/kg, or about 100 mg/kg. In some embodiments, no ataxia occurs, at for example a dose of at 500 mg/kg, i.v.
[00791 A therapeutically effective amount of GLYX peptide required for use in therapy varies with the form of the condition being treated, the length of treatment time desired, the age and the condition of the patient, and is ultimately determined by the attending physician. The desired dose may be conveniently administered in a single dose that is effective for two weeks, one week, 6, 5, 4, 3, 2, or 1 day, or as multiple doses administered at appropriate intervals, for example as two, three, four or more sub-doses per day.
[00801 An effective dose or amount, and any possible effects on the timing of administration of the formulation, may need to be identified for any particular composition of the disclosure. This may be accomplished by routine experiment as described herein, using one or more groups of animals (preferably at least 5 animals per group), or in human trials if appropriate. The effectiveness of any subject composition and method of treatment or prevention may be assessed by administering the composition and assessing the effect of the administration by measuring one or more applicable indices, and comparing the post-treatment values of these indices to the values of the same indices prior to treatment.
[00811 The precise time of administration and amount of any particular subject composition that will yield the most effective treatment in a given patient will depend upon the activity, pharmacokinetics, and bioavailability of a subject composition, physiological condition of the patient (including age, sex, disease type and stage, general physical condition, responsiveness to a given dosage and type of medication), route of administration, and the like. The guidelines presented herein may be used to optimize the treatment, e.g., determining the optimum time and/or amount of administration, which will require no more than routine experimentation consisting of monitoring the subject and adjusting the dosage and/or timing.
100821 While the subject is being treated, the health of the patient may be monitored by measuring one or more of the relevant indices at predetermined times during the treatment period. Treatment, including composition, amounts, times of administration and formulation, may be optimized according to the results of such monitoring. The patient may be periodically reevaluated to determine the extent of improvement by measuring the same parameters.
Adjustments to the amount(s) of subject composition administered and possibly to the time of administration may be made based on these reevaluations.
10083] Treatment may be initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage may be increased by small increments until the optimum therapeutic effect is attained.
[00841 The use of the subject compositions may reduce the required dosage for any individual agent contained in the compositions because the onset and duration of effect of the different agents may be complimentary.
1 '7 [00851 Toxicity and therapeutic efficacy of subject compositions may be determined by standard pharmaceutical procedures in c;. 11 cultures or experimental animals, e.g., for determining the LD50 and the ED50.
100861 The data obtained from the cell culture assays and animal studies may be used in formulating a range of dosage for use in humans. The dosage of any subject composition lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For compositions of the disclosure, the therapeutically effective dose may be estimated initially from cell culture assays.
100871 in certain embodiments, the GLYX peptide is administered as a preventative measure (i.e., before the prodrome phase). -hi certain embodiments, the GLYX
peptide is administered during prodrome. in certain embodiments, the GLYX peptide is administered at aura. By "at aura" is meant any time after the onset of aura and prior to the onset of migraine pain. In certain embodiments, the GLYX peptide is administered after the onset of migraine pain. -hi certain embodiments, the (JINX peptide is administered during the postdrome, e.g. to lessen the symptoms thereof.
[00881 The term "prevent," as used herein, refers to prophylactic treatment or treatment that prevents one or more symptoms or conditions of a disease, disorder, or conditions described herein (e.g., pain or migraine with aura and with or without allodynia).
Preventative treatment can be initiated, for example, prior to ("preexposure prophylaxis") or following ("post-exposure prophylaxis") an event that precedes the onset of the disease, disorder, or conditions (e.g., at migraine aura). Preventive treatment that includes administration of a GLYX peptide described herein, or a pharmaceutically acceptable salt or solvate -thereof, or a pharmaceutical composition thereof, can be acute, short-term, or chronic. The doses administered may be varied during the course of preventative treatment. See also: Kaniecki et al., "Treatment of Primary Headache: Preventive Treatment of Migraine." In: Standards of Care for Headache Diagnosis and Treatment. Chicago (IL): National Headache Foundation; 2004, p.
40-52.
Formulations 100891 The GLYX peptides of the disclosure may be administered by various means, depending on their intended use, as is well known in the art. For example, if compositions of the disclosure are to be administered orally, they may be formulated as tablets, capsules, granules, powders or syrups. Alternatively, formulations of the disclosure may be administered parenterally as injections (intravenous, intramuscular or subcutaneous), drop infusion preparations, or suppositories. For application by the ophthalmic mucous membrane route, compositions of the disclosure may be formulated as eyedrops or eye ointments.
These formulations may be prepared by conventional means, and, if desired, the compositions may be mixed with any conventional additive, such as an excipient, a binder, a disintegrating agent, a lubricant, a corrigent, a solubilizing agent, a suspension aid, an.
emulsifying agent or a coating agent.
[00901 DNA encoding the GLYX peptides, incorporated into an expression vector, can also be administered, using any of the known administration methods, to express of the GLYX
peptides in vivo.
100911 in formulations of the subject invention, wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants may be present in the formulated agents.
[0092] Subject compositions may be suitable for oral, topical (including buccal and sublingual), rectal, vaginal, aerosol and/or parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of composition that may be combined with a carrier material to produce a single dose vary depending upon the subject being treated, and the particular mode of administration.
10093] Methods of preparing these formulations include the step of bringing into association compositions of the disclosure with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association agents with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
[00941 Formulations suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pasfilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia), each containing a predetermined amount of a subject composition thereof as an active ingredient.
Compositions of the disclosure may also be administered as a 'bolus, eleetuary, or paste.
[0095] In solid dosage forms for oral administration (capsules, tablets, pills, dragees, powders, granules and the like), the subject composition is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, marmitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, acetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonhe clay; (9) lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof: and (10) coloring agents. In the case of capsules, tablets and pills, the compositions may also comprise buffering agents.
Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
[00961 A. tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropyimethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the subject composition moistened with an inert liquid diluent.
Tablets, and other solid dosage forms, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art.
[00971 Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. in addition to the subject composition, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofinyl alcohol, polyethylene glycols and fatty acid esters of sorbitan, cyclodextrins and mixtures thereof 5 [00981 Suspensions, in addition to the subject composition, may contain. suspending agents as, for example, ethoxylated i.sostearyi alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof 10099] Formulations for rectal or vaginal administration may be presented as a suppository, 10 which rna,,, be prepared by mixing a subject composition with one or more suitable non--irritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the body cavity and release the active agent Formulations which are suitable for vaginal administration also include pessaries, tampons, 15 creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
[001001 Dosage forms for transdermal administration of a subject composition includes powders, sprays, ointments, pastes, creams, lotions, gels, solutions, and patches.
[001011 For topical ocular administration compositions of this invention may take the form 20 of solutions, gels, ointments, suspensions or solid inserts, formulated so that a unit dosage comprises a therapeutically effective amount of the active component or some multiple thereof in the case of a combination therapy.
[001021 Pharmaceutical compositions of this invention suitable for parenteral administration comprise a subject composition in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions Of emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
1001031 Examples of suitable aqueous and nun-aqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate and cyclodextrins. Proper fluidity may be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
Combination Therapy 1001041 Any of the GLYX peptides described herein (e.g., GLYX-13) can be used alone or in combination with other agents to treat or prevent any of the diseases or conditions discussed herein. For example, in some combination treatments, the dosages of one or more of the therapeutic compounds may be reduced from standard dosages when administered alone.
1001051 The methods of the invention also comprise co-administration of a GLYX
peptide with an opioid, an antidepressant, an antiepileptie, a non-steroidal anti-inflammatory drug (MAID), a serotonin 5HT1 B/1 D agonist, an N-methyl-D-aspartate antagonist, or an anti-inflammatory compound.
1001061 The disclosure relates in certain embodiments to the use of a GLYX
peptide or peptides alone or in combination with one or more other antidepressant treatments, such as tricyclic antidepressants, MAO-I's, SSR1's, and double and triple uptake inhibitors and/or anxiolytic drugs for manufacturing a medicament for treating migraine (e.g., episodic migraine, chronic migraine, retinal migraine, ophthalmoplegic, migraine, acephalgic migraine, migrainous disorder, menstrual migraine, abdominal migraine, childhood periodic syndromes, or cluster headache). Exemplary drugs that may be used in combination with a GLYX peptide include Anafranil, Adapin, Aventyl, Elavil, Norpramin, Pamelor, Pertofrane, Sinequan., Surmontil, Tofranil, Vivactil, Parnate, Nardil, Marplan, Celexa, Lexapro, Luvox, Paxil, Prozac, Zoloft, Welibutrin, Effexor, Remeron, Cymbalta, Desyrel (trazodone), and Ludiomill.
1001071 in certain embodiments, the opioid is selected from the group consisting of alfentanil, butorphanol, buprenoiphine, dextromoramide, dezocine, dextropropoxyphene, codeine, dihydrocodeine, diphenoxylate, etorphine, fentanyl, hydrocodone, hydromorphone, ketobemidorie, loperami d.e, levorphanol, levomethadone, meptazinol, methadone, morphine, morphine-6-g1ucuronide, nalbuphitte, naloxone, oxycodone, oxymowhone, pentazocine, pethidine, piritramide, propoxyphene, remifentanil, sulferitanyl, tilidine, and tram.adol.
[001081 In certain embodiments, the antidepressant is selected from the group consisting of adinazolam, ataproclate, amineptine, amitriptyline/chlordiazepoxide combination, atiparnezole, azainian.serin, bazinaprine, beforatinc, bifeitnelane, binodaline, bipenamol, brofaromine, caroxazorte, cerielamine, cianopramine, cimoxatone, citalopram, clemeprol, clovoxamine, dazepinil, deanol, demexiptiline, dibenzepin, dothiepin, dr oxidopa, enefexine, estazolam, etoperidone, femoxetinc, fengabine, fezolamine, fluo.tracen, ida.zoxan, indalpine, indeloxazine, iprindo1e, levoprofiline, lithium. litoxetine, lofepraTiline, medifoxamine, metapramine, metralindole, rnianserin, milnacipran, minaprine, mirtazapine, montirelin, nebracetarn, nefopam, nialamide, notnifensine, norfluo.xetine, orotirelin, oxaflozane, pinazepain, pirlindole, pizotyline, ritanserin, rolipram, sercloremine, setiptiline, sibutramine, sulbutiamine, sulphide, teniloxazirte, thozalinone, thyroliberin, tianeptine, tiflucarbine, trazodone, tofenacin, tofisopam, toloxatone, tomoxetine, veralipride, viloxazine, viqualine, zimelidine, and zometapine.
[001091 In certain embodiments, the antiepileptic is selected from the group consisting of carbamazepine, flupirtine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, retigabine, topiramate, and vaiproate.
[001101 in certain embodiments, the NSAID is selected from the group consisting of acemetacin, aspirin, cele,coxib, deracoxib, diclofenac, diflunisal, ethenzamide, etofenarnate, etoricoxib, fenoprofen, .flufenainic acid, .flurbiprofen, lonazolac, lornoxicam, ibuprofen, indomethacin, isoxicam, kebuzone, ketoprofen, ketorolac, naproxen, naburnetone, niflurnic acid, sulindac, tolmetin, piroxicam, mec,lofenarnic acid, mefenamic acid, meloxicarn, metamizol, mofebutazone, oxyphenbutazone, parecoxib, phenidone, phertylbutazone, piroxicarn, propacetamol, propyphenazone, rofecoxib, salicylainide, suprofen, tiaprofenic acid, t enox ic am, valdecoxib, 4-(4-cyclohexy1-2-methyloxazol-5-y1)-2 -fl u o rob en zene sulfonami de, N-[2-(cyclohexyloxy)-4-n itr op he n yl] rn e th a ne s ulfo narnide, 2-(3,4-d iflu o ro p h e ny1)-4-( 3 -hydroxy-3 -met hy lb utoxy)-5- [4- ( met 111õ,ls ulfo nyl)r) henyl] -3(2H)-pyrid az inone, and 2-(3,5-di fluor op h e,n.y1)-3- [4- (me thy Is ulfon yl)p e I] -2-cycl op ent en -ne.
[001111 In certain embodiments, the serotonin 5fITIB/ID agonist is selected from the group consisting of eletriptan, frovairiptan, naratriptan, rizatTiptan, s LI
inatriptan, and zoimitriptan.
[0011.21 In certain embodiments, the N-methyl-D-aspartate antagonist is selected from the group consisting of ama.nta.dine, aptiganel, besonprodik budipine, conantokin G, delucemine, dexanabinol, dextromethorphan, dextropropoxyphene, felbamate, fluorofelbamate, gacyclidinc, glycine, ipenoxazone, kaitocephalin, ketamine, ketobemidone, lanicemine, licosiinel, midafotel, -me-mantine, fl-methadone. D-morphine, milnacipran, neramexane, orphenadrine, remacemide, sulfazocine, FPL-12,495 (racemide metabolite), topiramate, (aR)-a-amino-5-chloro-1-(ph o sphonomethyl)- I H-b en zi midazole-2-propanoi c acid, 1 -aminocycl op entane-carbox.ylic acid, [5 -(arn int) me thyl)-2 - [ [ [.(5 S)-9-chl oro-2,3,6,7-te trahydro-2,3-dioxo- 1 H- EI-pyrido [1,2,3 -de] quinoxalin-5-yll a.c etyl] amino] p he noxy ] -acetic acid, a- a mino -2-(2-pho sp hono e thyl)-cycluhexanepropanoic acid, a-amino-4-(phosphonomethyl.)-benzeneacefic acid, (3E)-2-amino-4 -(ph o sp h 0110/11 ethyl)-3 - h eptenoic, acid, 3 - [(iE)-2-earb oxy-2 -p h enyletneri yli -4 ,6-dichloro- 1H-indote-2-carboxylie acid, 8-chloro-2,3-dihydropyridazino14,5-b]quino.1ine-1,4-dione 5-oxide salt with 2-hydroxy-N,N,N-trimethyl-ethanaminium, N '42-chloro-5-(m.ethylthio)phen:µ,71]-N-methyl-N- [3 -(rn eth y ith io )ph eny I] -guanidine, N'42-chloro-5-(methylthio)phertyll -N-methy l-N-[3-[(R)-methylsulfiny1iphenyl]-guanidine, 6-ehloro-2,3,4,9-tetrahydro-9-methyl-2,3-dioxo-1H -indeno[1,2-b]pyrazine-9-acetic acid, 7-chlorothiokynurenic acid, (3S,4aR,6S,8aR)-decahydro-6-(phosphonoMC thyl)-3-isoquinolinecarboxylic acid, (¨)6,7-dichlo ro- 1,4 - d ihydro-5 - [3 -(tri ethoxym eth yl)-5-(3-pyri d iny1)-4- H-1 ,2,4-triazol -4 -2,3 -cin inox alinedione, 4,6-di ehl oro-3 -[(E)-(2-oxo- 1 - p he ny1-3 -pyrrol id inylid ene)methyt] 1H- ind o.le-2 -carboxylic acid, (2R,4 S)-re 5,7 -dich ro - 1,2,3 ,4-tet ra.hydro -4 - apheny kunino)carb onyl] amino.] - 2-citi i no linecarbox.ylic acid, (3R,4 ihydro-344-h ydroxy-4-(phen y ethy1)- 1 -pip eri d iny11-2H- I -benzopyran.-4,7-diol, 2- [(2,3 -dihydro- 1 H- inden-2-yDaminol-acetam ide, 1,4-dihydro-6-methy1-5-V me thy la mino)me thyll -7-nitro-2,3-quinoxalinedione, [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]noa-1(7)-en-2-Aethyl]-phosphonie acid, (2R.,6S)-1,2,3,4,5,6-hexahydro-3-[(2 S)-2-methoxypropy11-6,11 , 11 -tri methy1-2,6-met hano-3 -benzazocin-9-ol., 2-hydroxy-5-[ [(pent afluo rophe ri yprne thyl]am ino] -benzoic acid, 1 -12--(4-hydroxyph enoxy)ethy11-4 - [(4-methylphenyl)me thy I] - 4 -p eridinol, 1-[4 - ( 1H-imida zoi-4 y1)-3 -b Mynyi] -4 -( phe ny lmethyl)-piperidine, 2-triethyl-6-phenylethyny1)-pyridine, 3-(phosphoriomethyl)-L-phenylalanine, and 3,6,7-tetrahy dro-2,3-dioxo-N-p henyl- 111,5 -pyri do [1,2,3 -de] quinoxaline-5-acetamide.
:-30 [001131 la certain embodiments, the anti-inflammatory compound is selected from the group consisting of aspirin, celecoxib, cortisone, deracoxib, diflunisak etoricoxib, ferioprofen, ibuprofen, ketoproferi, riaproxen, prednisolone, sulindac, tolmetin, piroxicam, mefenamie acid, meloxicam, phenylbutazone, rofecoxib, suprofen, valdecoxib, 4-(4-cyclohexy1-2-methyloxazol-5-y1)-2-fluorobenzenesulfonamide, N- [2-(cyclahexyloxy)-4- trophenyl]
methanesu tfon amide, 2-(3,4-di fitioropheny1)-4-(3-hydroxy-3-methy b u tox.y)-5- [4-(methy sulfony Opheny11-3 (2H)-pyri daz ino neõ and 2-(3,5-difluoropheny1)-3- [44 methy s ulfonyl)p heny1]-2-cyclop enten-l-one.
[001141 The disclosure has multiple aspects, illustrated by the following non-limiting Examples.
EXAMPLES
Examolel [001.151 The studies described, herein utilized extracellular multi-site electrophysiological monitoring of SD rate of propagation, and two-pholon laser scanning microscopy for real-time imaging of SD-evoked changes in dendritic spine size, in in vitro hippocampal slices. The effect of a novel NMDAR. receptor functional glycine site partial agonist, GLYX-13 was examined on the threshold and rate of propagation of SD, and real-time effects of SD on dendritic spine mutphology. GLYX-13 occasionally completely prevented the induction of SD
by a local increase in extracellular potassium concentration, and consistently slowed its propagation rate. The passage of SD through the hippocampal CA1 region produced a rapid retraction of dendritic spines which reversed after neuronal depolarization had recovered.
GLYX-13 improved the rate and extent of return of dendritic spines to their original sizes and locations following SD, indicating that the drug and others that modulate NIVIDA receptor activity could protect synaptic connections in the brain from possible damage from repeated migraine attacks.
General Methods Drugs [001161 All external and patch pipette solutions were made with deionized distilled water (resistance > 18 mn cm 2; Milli-Q system), The chemicals for making extra- and intracellular solutions were purchased from Sigma-Aldrich (St. Louis, MO, -USA).
Alex.aFittor 594 was purchased from Molecular Probes.
Slice Preparation and Evil-aceIlular Recordings [001171 Experiments were performed on hippocampal slices from 14 to 21 day old Sprague-Dawley0 rats (Taconic Farms, Hudson, NY). Rats were deeply anaesthetized with isofluorane, sacrificed, and the brains quickly removed and placed in oxygenated (95% 02 5%
CO2), ice-cold artificial cerebrospinal fluid (ACSF) containing (in rnM): 126 NaCl, 2.5 KC1, 2.6 CaC12, 5 1.3 MgC12, 1.25 NaH2PO4, 26 NaHCO3, and 11 Glucose. The brain was hemisected, the frontal lobes cut off, and individual hemispheres glued using cyanoacrylate adhesive to a stage immersed in ice-cold ACSF oxygenated continuously during slicing. 400 um thick coronal slices containing the hippocampas were cut using a -vibratome (Leica 1200s), and transferred to an interface holding chamber for incubation at room temperature for a minimum of I hour 10 before transfer to a Haas-style interface chamber for recording at 32 'C. Slices were perfused with ACSF (4mIlmin; ACSF mM: NaCI 126; KC1 3; NaH2PO4 1.25; MgCI 1.3; CaCl2 2.5;
NaHCO3 26; glucose 10) saturated with 95% 02/5% CO2 prior to start of the experiment, and all drugs were bath-applied.
[001181 Extracellular recordings were carried out using a MultiClamp 700B
(Axon 15 instruments) with Clampex (v. 9), filtered at J. kHz and digitized at 3 kHz. Low resistance (1-2 Mc2 after filled with ACSF) recording electrodes were made from thin-walled borosilicate glass inserted into the apical dendri-tic region of the Schaffer collateral termination field in stratum radiatum of the CA.1 region, at approximately 150 rum distance intervals from the SD initiating pipette, to monitor the spread of S.D. The submerged recording chamber was mounted on a 20 Zeiss Axioskop 2FS upright microscope equipped with infrared differential interference contrast (DIC) optics. A 10x objective was used to image slice luminance change caused by SD. Luminance changes were imaged every 100 ms with a cooled CCD camera (CoolSNAP
HQ) controlled by a PIT master system. Electrophysiological data were analyzed with Clampfit 9. Imaging data were digitized and reconstructed with ImageJ
25 [001.191 A bipolar stainless steel stimulating electrode (PHC, Bowdoin, ME) was placed in Schaffer collateral-commissural fibers in the CA3 region, and current pulses were applied with stimulus intensity adjusted to evoke approximately 50% of maximal fEPSPs once each 30 s (50 to 100 pA; 100 ps duration). Electrical stimulation from an ISO-Flex isolator was controlled by a Master eight-pulse generator (AMPI, Jerusalem, Israel) and triggered by a Multielamp 700B
(Molecular Devices, Sunnyvale, CA). Signals were digitized with a Digidata 1322 and recorded using a Multiclamp 700B amplifier. fEPSP slope was measured by linear interpolation from 20-80% of maximum negative deflection, and slopes confirmed to be stable to within 10% for at least 15 min before commencing an experiment. Data were analyzed using Clampfit (Version 9; Axon Instrument) on an IBM-compatible personal computer. Evoked fEPSPs (50%
of maximum amplitude, 2-4 mV) were recorded in the apical dendritic field in stratum radiatum for a stable baseline period of at least 30 min.
Induction of Hippocampal Spreading Depression [001201 Acute coronal slices of hippocampus were transferred to a submerged recording chamber on a microscope stage and perfused with warmed ACSIF (32 C) where extraeellular [K] was raised to 8 niM at a perfusion rate of 3 mlimin. Spreading depression was initiated by pressure-injecting puffs of 3M KC1 through a glass pipette. Pressure pulses of 8-10 psi that lasted 50-100 ms were driven by a Picospritzer TT (Parker Hannifin, Hollis, NH) Pipette resistances were 2 0.2 Mil when filled with 3 M KO.
Dynamic imaging analysis of dendritic spine retraction/recovery [001211 After loading a CA1 pyramidal neuron in a hippocampal slice with Alexa Fluor 594 (100 1,1\4) for 15 minutes, tertiary dendrites were imaged using a using a customized two-photon. laser-scanning Olympus BX61W1 microscope equipped with a 60x11.1 nA
water immersion infrared objective plus 4x digital zoom, as described previously (Zhang et al., 2008).
XYZ scanning mode in a range of +1- 3 um from focused layer was used to avoid movement bias, with a z step interval of 0.5 um, and each image took 0.45 second to finish, for a single depth profile time of 7 seconds. Great care was taken to avoid both saturation of fluorescence and any signs of phototoxicity to small dendritic spines from too much excitation light. Depth profiles were repeated at 5 min intervals to reduce possible dye photobleaching and phototoxicity. A. .MailTai laser (Solid-State Laser, Mountain View, CA) tuned to 810 nm was used for excitation, and image acquisition controlled by Olympus FluoviewFV300 software (Olympus America, Melville, NY) Epifluorescence was detected with photomultiplier tubes of the confocal laser scan head with pinhole maximally opened and emission spectral window optimized for signal over background. in the rransfluorescence pathway, a 565 nm dichroic mirror was used to separate green and red fluorescence, and passed through HQ525/50 and HQ605150 emission filters, respectively, to eliminate transmitted or reflected excitation light (Chroma Technology, Rockingham, VT), and detected simultaneously by two photomultiplier tubes. The figures show collapsed images from the entire 6 um Z-profile, and these projections were used to calculate intensity as an index of spine volume.
Data Analyses [001.221 Recording signals were filtered through an. eight-pole Bessel low-pass filter with a kHz cutoff frequency and sampled by Clampex (V. 9) with an interval of 100 irs. After fEPSP
slopes were calculated with Clampfit (V.9), the data were further processed with Origin 6.1 (Microcal Software, MA) and presented with CordDraw 10 (Core!, Ottawa, Ontario, Canada).
All data were analyzed by one-way analysis of variance (ANOVA), or Student's t-test using SPSS software (SPSS Inc., Chicago, IL). Significance level was preset to P <
0.05. Data are presented as mean + SEM across experiments.
Results Focal, high [K+j-indueed spreading depression in field CAI of hippocarnpal slices [001231 in artificial cerebrospinal fluid (ACSF) where [1(10 was elevated to 8 niM at 32 'V, a single local puff (100 ms) of 3 M [Kb o onto a field in CA.1 stratum radiatum (Figure 1, top left) reliably induced. SDs which spread at propagation rates of 9 71: 5.4 mm/min (n = 16) over the entire CA1 region of the hippocampus. SD characterized as a negative field potential shift (Figure 1, top right) showed a maximum shift of -8 1.5 niV (n=30) in the stratum radiatum synaptic layer of the hippocampal CA1 region which typically lasted more than 45 seconds.
[001241 SD was induced every 10 minutes to test whether the area of the negative potential shift (Figure 1, top right, hatched area), a measure of the effective magnitude and duration of extracellular space conduction of K.+, was stable with repeated SDs. While the areas of negative potential shifts recorded from the initiating electrode were larger than at the distal recording electrode 600 um away (Figure 1, bottom), there were no significant differences in amplitude or propagation speed of the individual episodes of repeated sequential SDs elicited at 10 minute intervals at either site (Bonferroni Multiple Comparison Test, P> 0.20). These results indicate that reproducible SD negative potential shifts can be stably, repeatedly evoked in field CA.1 of the hippocampus, at least for the first ten.
GLYX-13 suppresses the propagation and increases the refractory period of hippocarnpal spreading depression [001251 To test the hypothesis that the novel NMDA receptor glycine coagonist site partial agonist GLYX-13 could raise the threshold for or prevent SD by regulating NMDA
receptor activation within a physiological range and preventing excess activation, GLYX-13 was bath--applied at 1, 10, or 50 um to hippocampal slices for 30 min prior to brief ejection of high [K+]
(1 miN4 in patch pipette) into stratum radiatum of the CAI region and attempted to elicit SD. A
dose-response relation was constructed based on time of high [K-1-I ejection first in naive slices, and then after a 30 minute bath application of GLYX-13 at each of the three test concentrations (1,10, or 50 M), while recording DC potential to detect SD.
[001261 After at least three SDs were initially evoked in drug-free ACSF, slices were perfused with GLYX-13 and continued to elicit SDs every ten minutes. As illustrated in Figure 2, top, for 10 t.tM GLYX-13, there were no significant differences between the baseline areas of individual sequential episodes of SD at the initiating site (Bonferroni Multiple Comparison Test, P >0.20), indicating that GLYX-13 did not alter the initiation of SD.
[001271 GLYX-13 was next tested to ascertain whether affected the relationship of SD
amplitudes at near (proximal) and far (distal) recording sites with repeated SDs. The slice was perfused with 10 uM GLYX-13 and continued to elicit SDs every ten minutes (Figure 2, bottom). Bonferroni Multiple Comparison Test (P >0.20) again showed no significant difference between the areas of individual sequential episodes of SD in control slices. CiLYX-13 did not affect the initiation of -the negative potential shift of SD at the proximal recording site.
[001281 SD amplitudes at the initiating site were con-elated with areas of negative potential shifts of SD at the remote recording (Figure 2, bottom). Therefore, proximal/distal area ratio in absence and presence of GLYX-13 was compared. As illustrated in Figure 2, bottom, the area ratio between remote and initiating sites was dramatically reduced in the presence of 10 it M
GLYX-13 by the application of the sixth SD (6th SD). A two way ANOVA indicated three significant effects: 1) time effects repeated SDs in the same slices (F(1, 12)=5.17, p <0.05) over all observations; 2) effects from drug treatment (F(1,12)=5.07, p <0.05); and 3) an interaction of time with treatment (F(1,12)=30.91, p <0.01). These results indicate that recurrent negative potential shifts of SD alter the amplitude ratio between remote and initiating sites; and that this reduction was markedly enhanced by GLYX-13. These findings show that GLYX-13 can significantly suppress the propagation of SD through the brain, particularly after multiple SD
events.
[001291 In the preceding studies, it was demonstrated that GLYX-13 can limit the propagation of SD by reducing the amplitude of the negative field potential shift and slowing the conduction speed, effects that were largest after multiple SDs. By shortening the interval between each SD initiation, it was discovered that each SD in control slices had an absolute refractory period of 3-4 minutes for the next successful SD = 7).
10 1,t1\4 GLYX-13 prolonged this refractory period to 5-6 minutes (n = 6). A.s shown in Figure 3, SD could be successfully evoked five minutes after a previous SD in a control slice (Control), but could not be elicited in a slice treated with GUYX-13 (GUY-X-13 30').
Measuring SD propagation using intrinsic changes in optical density produced by SD-induced extracellular space volume shifts [001301 SD elicits profound shrinkage of the extracellular space volume as fluid rushes in to depolarized cells and they swell, and this can. be seen as changes in intrinsic optical density in vivo. Such luminance intensity changes could also be readily detected in brain slices using transmitted light DIC microscopy. Figure 4A shows that an SD "aura" of increased luminance spreads from the initiating pipette and propagates across the slice, and can be used to calculate SD conduction velocity (Figure 4B). The time course of increased luminance correlated well with maximal negative potential shift of SD using electrophysiological recordings. Therefore, calculating the time course of luminance changes with distance provides an accurate and convenient way to measure SD conduction velocity.
[001.311 To determine if repeated SDs show the same conduction velocity, the luminance changes were monitored over 5 points separated by 150 um as diagrammed at the top of Figure 4A. A one way ANOVA with repeated measures indicated that SD maintained a steady transmitting speed from P1 to P5 (F(5, 35)=2.42, p >0.05) within an individual slice. Therefore, the transmitting speed could be used from PI to P5 to test SD stability over successive episodes. The average propagating speed of SD was 9.07 0.55 inn 'mm, ranging from 7,54 to 11.14 mm/mmn (n=16).
[001321 To test whether repeated episodes of SD maintained a stable speed and if GLYX-13 affected SD conduction velocity, a ANOVA test was used with repeated measures to analyze 6 subsequent SDs as illustrated in Figure 5. Analysis revealed a significant difference between control and GLYX-13 treated slices (F(1,50)=3.66, p <0.01). SD sequence accounted for 38.5%
of total variance, indicating that SD propagation speed significantly slowed with increasing SD
number (F(5,50)=14.01, p <0.01). Although the GLYX-13 effect on SD propagation speed 5 over all repeated SDs did not reach significance in the two-way ANOVA, there was a significant interaction between number of SD and GLYX-13 treatment (F(5,50)=2.53, P
<0.05), reflecting that GLYX-1 3 (filled circles) significantly decreased SD
propagation speed only by the seventh SD.
Spreading depression causes CA1 pyramidal neuron dendritic spines to reversibly shrink in volume [001331 The anatomical microarchitecture of pyramidal neuron dendrites in the brain is 1.0 surprisingly labile in response to a variety of stimuli.
Depolarization, oxygen/glucose deprivation and N-methyl-D-aspartate have all been shown to produce retraction of dendritic spines in hippocampal CA1 pyramidal neurons in vitro. To examine the response of spines to SD, single CA1 pyramidal neurons were filled with the fluorescent dye Alexafluor-594 and imaged dendritic spine shape using serial z-stack sections (0.2 urn steps spanning 5 lim) 15 collected from 2-photon laser scanning microscopy. Thirty minutes after loading of Alex.aFluror-594 into CAI pyramidal had reached equilibrium distribution within the neuron, SDs were initiated by brief ejection of high [K+] (1M in the patch pipette) into stratum radiatum of the CA1 region of hippocampal slices where Schaffer collateral axons synapse on the apical dendrites of CAI pyramidal neurons. As illustrated in Figure 6A and 6B, the 20 depolarization produced by SD did elicit substantial spine shrinkage as measured by collapsed z-stack fluorescence amplitude, with spine volume completely recovering 20-30 minutes after the first SD. This confirms that one of the sequelae of SD-induced depolarization is alteration in dendritic spine morphology.
GLYX-13 improves dendritic spine recovery following spreading depression [001341 Finally, the effects of GLYX-13 were examined on the dynamic morphological 25 responses of dendritic spines to SDs. GLYX-13 was investigated whether it could either lessen the shrinkage of spines in response to SD, or improve their recovery. Figure 6A illustrates spine shrinkage in response to two episodes of SD in a control pyramidal neuron, while Figure 6B
exemplifies the same process in the presence of 10 m.1%.1 GLYX-13. ANOVA. for repeated measures reached significance (F(8,64)=17.53, p<0.001) for fluorescent intensity measured from dendritic spines like the one illustrated at the top of Figure 6C, and that this significance mainly came from the post-SD time courses (F(8,64)=6,18, p<0.01), revealing that, while GLYX-13 (filled circles) did not alter the shrinkage caused by SD, it did rescue the recovery of spine size following SD (F(8,64)=2.81, p<0.05).
Example 2 [00135] Hippocampal Slice Preparation: Experiments were performed using Sprague-Dawley0 rats (Taconic Farms) .14 to 21 days of age. Rats were deeply anaesthetized with isofluorane, sacrificed, and the brains quickly removed and placed in oxygenated (95% 02 ---5% CO2), iced-cold artificial cerebrospinal fluid (ACSF) containing (in miv1):
126 NaC1, 2.5 KCl, 2.6 CaC12, 1.3 MgC12, 1.25 Na.H2PO4, 26 NaHCO3, and 11 Glucose. The brain was hemisected., the frontal lobes cut off, and individual hemispheres glued using cyanoacrylate adhesive to a stage immersed in ice-cold ACSF oxygenated continuously during slicing. 400m thick coronal slices containing the hippocampus were cut using a Vibratome (Leica. I200s), and transferred to an interface holding chamber for incubation at room temperature for a minimum of 1 hour before commencing the experiment.
[001361 induction of Hippocampal Spreading Depression: Acute corona! slices of hippocampus were transferred to a submerged recording chamber on a microscope stage and perfused with warmed ACSF (32 degree centigrade) where extracellular [K+1 was raised to 8 inM at a perfusion rate of 3 milmin. Spreading depression was initiated by pressure-injecting puffs of 3M l(C1 through a glass pipette. Pressure pulses of 8-10 psi that usually lasted 50 ms were driven by a picospritzer. Pipette resistances were 2 0.2 Mn when filled with 3 M KO.
[001371 Electrophysiological. Recording Methods: Extracellular recordings were carried out using a MultiClamp 70013 (Axon Instruments) with Clampex (v. 9), filtered at 1 kHz and digitized at 3 kHz. Low resistance (1-2 MO. after filled with ACM recording electrodes were made from thin-walled borosilicate glass inserted into the apical dendritic region of the Schaffer collateral termination field in stratum radiatum of the C,A.1 region, at approximately 150 mm distance intervals from the SD initiating pipette, to monitor the spread of SD. The submerged recording chamber was mounted on a Zeiss A.xioskop 2FS upright microscope equipped with infrared differential interference contrast (DIC) optics. A 10x objective was used to image slice luminance change caused by SD. Luminance changes were imaged every 100 ms with a cooled CCD camera (CoolSNAP HQ) controlled by a PTI -master system.
Electrophysiological data were analyzed with Cla.mpfit 9. Imaging data were digitized and reconstructed with imageJ (NTH). All experiments were conducted under an approved protocol in compliance with National Institutes of Health guidelines [001381 The findings of Example I are investigated relating to women and adolescent patients. The experimental protocol was used to initiate spreading depolarization (Si)) in the CA1 region of the hippocampus inbrain slices in vitro. To better observe the distance of spreading depression from the initiation site and SD propagation speed over a longer range visually, the 1.0x objective of Example 1 was replaced with a 4x objective to enlarge the viewing domain to 1.6 mm. The recording chamber was modified to perfuse the slice from both sides, more efficient perfusion not only provided sufficient oxygen to the brain slice, but also helped to maintain stable extracellular milieu since each episode of spreading depression causes a dramatic ion composition change both extracellularly and intracellularlly.
[001391 Two groups of 2 month-old, uvariectomized Sprague-Dawley female rats were included in the current cohort study. One group of ovariectornized rats were provided with daily injections of estrogen for 7 days since the 7th post-operation day, while the others were only injected with oil vehicle as controls for 7 days before conducting experiments.
[001401 The luminance changes were visually categorized following a puff of 3 M
potassium as failure (<100 mm), local spreading (>100.mm; <800 mm); or full spread (>800 mm). SD induction was attempted in 39 slices from 8 oil--treated rats and 35 slices from 7 estrogen-treated rats. Table I summarizes the frequency of occurrence of SD
evoked by the same method in the two groups. in the oil-treated group, the failure rate was significantly higher than in the estrogen treated group (Chisquare test, P-0.014), indicating that estrogen itself enhances the propensity of brain tissue to exhibit SD upon focal depolarization.
Table 1 Group Non-SD Localized SD -Full SD Total Oil Treated 13 21 5 39 Estrogen Treated 6 23 6 35 [001411 Luminance changes were used to estimate the transmitting velocity of spreading depression as shown in Figure 7 below. Propagation velocities were calculated from both localized and full SD induced by focal 31M. potassium puffs, by dividing the distance of SD
between observation sites by time that SD took to travel between these observation sites. As illustrated in Figure 7, mean spreading speed in slices from estrogen-treated rats was 0.121+
0.013 minis, significantly faster than the speed of propagation in slices from of oil-treated control rats (0.083 0.005 mm/s, P<0.05, Student's t-test. These data indicate that estrogen plays a significant role in enhancing both the propensity and speed of SD in hippocampus, and probably in neocortex as well.
in [001421 Testing of how estrogen affects the severity of SD by measuring the maximum distance of propagation of SD away from the initiation site was conducted. As shown in Fig 8, the spreading end point along the Schaffer collateral pathway estimated by averaging the distance of the observation site that showed minimum detectable luminance changes (>5%
change from baseline) from the initiation site with the distance of the close neighboring observation site that exhibited undetectable luminance changes, and measuring this distance from the initiation site. As shown in Figure 8, the SD in slices from estrogen-treated rats traveled a significantly longer distance (0.594 0.071 mm; n=18) than SD in slices from oil-treated rats (0.394 + 0.051.mm; n=16, P<0.05, Student's t-test). Hence, SD in estrogen-treated rats was not only more readily elicited, but propagated longer distances.
00143[1 10 11\4. GLYX-13 was then added to the perfusate after 2 &is were induced 10 minutes apart, and continued to induce SD each 10 minutes to determine whether the velocity and scale of SD were affected. Figure 9 shows the typical differences of evoked SD in a slice from an estrogen-treated rat before application of GLYX-13 and after a 50 minute exposure to 10 1,1\4 bath-applied GLYX-13. The luminance changes at 10 observation sites were measured to assess the effects of GLYX-13 on SD. Although SD was still readily evoked, as shown in Figure 9B, Figure 9A clearly shows that luminance changes associated with SD
were delayed in the presence of GLYX-13. A. paired t-test showed that GLYX-13 significantly reduced mean SD transmission velocity from 6.56 0.57 mm/min to 4.96 0.28 mm/min (n=5, P<0.01, paired nest). The same experiments in hippocampal slices from oil-treated rats were conducted.
3 0 While GLYX-13 decreased mean SD transmission velocity from 5.09 0.61 min/min to 4.50 +
0.39 nunlinin (n=5), this decrease did not reach statistical significance.
[001441 A two-way repeated ANOVA was also carried out to explore the effect of GLYX-13 on SD propagation speed across the two groups. As Figure 10 illustrates, the first significance comes from estrogen treated rats before and after application of (F(1,8)=3.1;p<0.05); and the second significance arises from preexposure of between the two groups (F(1,8)=4.2; p<0.05). These results indicate that GLYX-13 has a stronger effect in estrogen treated rats, significantly slowing transmission velocity of SD to the level of oil-treated rats.
Example 3 Methods Animals [001451 Adult male (2-3 month old) Sprague-Dawley (SD) rats were purchased from Harlan (USA). Rats were housed in Lucite cages with aspen wood chip bedding, maintained on a 12 hour:12. hour light:dark cycle (lights on at 5 AM), and given ad libitum access to Purina rat chow (USA) and tap water throughout the study.
Traumatic brain ii-ijury induction [001461 Single blast-induced traumatic brain injury was induced, modified for use in rats according to the protocol of Goldstein et al. (Goldstein, LE, et al. (2012) "Chronic traumatic encephalopathy in blast-exposed military veterans and a blast neuratrauma mouse model,"
Science Translational Medicine 4:134ra160.) Adult male Sprague-Dawley rats were anesthetized by isofturane, ear plugs were inserted into both of the rat's ears, and the rat received a single ¨ 42 PSI blast of helium generated by puncturing, 0.014 inches of polyester films Sham controls were placed outside of the blast radius. As follows Animals were dosed with rapastinel (3 mg/kg IV) or 0.9% sterile saline vehicle (1 milkg IV) 1 hour post-blast Rats were first anesthetized using 3.5-4% isoflurane, then their ears were protected with 1.5 x 1.5 mm foam plugs (Pura-Fit ear plugs, Moldex-Metric INC, Culver City, California). The rats were placed into head access rodent thoracic restrainers (Stoelting, USA) to protect their bodies while allowing the heads to move freely, with the heads 10 cm from the end of the aluminum shock tubes (183 x 61 cm; L-3 Applied Technologies, USA). Rats received a single ¨42 PSI
blast of helium generated by puncturing 0.014 inches of polyester film. Sham controls were placed outside of the blast radius. Animals were dosed with rapastinel (3 mg/k2 IV) or 0.9%
sterile saline vehicle (1 mIlkg, IV) 1 hour post-blast. Latency to recover from anesthesia was recorded (Figure 11A). Recovery was defined as displaying eyeblink and righting reflexes, and normal ambulation (normal rhythmic gate, non-circular gate, fully supporting body weight, evidence of some sniffing and exploratory behaviors). Animals were dosed with GLYX-13 (3 5 mg/kg IV) or 0.9P/0 sterile saline vehicle (1 mUkg IV) 1 hour post-blast.
N ¨ 4-6 per group; * P
<0.05 (Figure 11A) ANOVA..
1001471 Positive emotional learning (PEL) Figure 11B shows the results of a single 3 min Positive Emotional Learning (PEL) test session conducted 24 hours post-blast using a between subjects design. N -= 4-6 per group. Fisher's PLSD post hoc test was used to evaluate results 10 (rapastinel TBI vs. vehicle -H TBI).
1001481 Heterospecific rough-and-tumble play was conducted as previously described (Burgdorf, J., et al. (20.11) "Positive emotional learning is regulated in the medial prefrontal cortex by G1uN2B-containing NMDA receptors," Neuroscience 192:515-523), and testing occurred 3 hours and 2 weeks post-dosing. Heterospecifie rough-and-tumble play stimulation 15 was administered by the experimenter's right hand. Animals received 3 mm of 1-3eterospecific rough-and-tumble play that consisted of alternating 15 sec blocks of heterospec,ific play and 15 sec of non-stimulation. High frequency ultrasonic vocalizations (USVs) were recorded and analyzed by sonogram with Avasoft SA.Slab Pro (Germany) as previously described (Id.).
Frequency modulated 50-kHz USVs that occurred during each of the non-stimulation periods 20 were quantified to measure PEL. Animals were not habituated to play stimulation before testing.
Results 1001491 As shown. in Figure 11A, animals that received TBI showed longer recovery times from anesthesia in comparison to sham control animals 13) = 4L7 , P < 0.05]. As shown in Figure 11B, rapastinel (3 mg/kg IV) rescued TBI-induced suppression of positive emotional 25 learning [F(2, 12) ¨ 10.0, P < .05; Fisher's PLSD post hoc test rapastinel TBI vs. vehicle sham vs. vehicle Tat vs., P <0.05]. In addition, anesthesia recovery time was not significantly correlated with rates of PEI., [r(15) = -0.14, P > .05]. in a positive emotional learning test, a single dose of rapastinel (3 mg/kg IV) completely rescued the deficits in learning and emotion induced by TBI. Thus, in this preclinicat niodel, rapastinel was effective in treating the core cognitive and affective symptoms of TBI and rapastinel appears the have therapeutic potential for the treatment of PTSD.
EQUIVALENTS
[001501 While specific embodiments of the subject disclosure have been discussed, the above specification is illustrative and not restrictive. Many variations of the disclosure will become apparent to those skilled in the art upon review of this specification.
The full scope of the disclosure should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with. such variations.
[001511 Unless otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, parameters, descriptive features and so forth used in the specification and claims are to be understood as 'being modified in all instances by the term "about"
Accordingly, unless indicated to the contrary, the numerical parameters set forth in this specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the disclosure.
[001521 All publications and patents mentioned herein, including those items listed below, are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference.
in case of conflict, the present application, including any definitions herein, will control.
Claims (26)
1. A method for treating migraine in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound represented by:
or pharmaceutically acceptable salt thereof.
or pharmaceutically acceptable salt thereof.
2. The method of claim 1, wherein the compound is administered to the patient with a dose of about 0.01 mg/kg to about 1000 mg/kg of about 1 mg/kg to about 500 mg/kg of the compound.
3. The method of claim 1 or 2, wherein the migraine is episodic migraine, chronic migraine, retinal migraine, ophthalmoplegic migraine, acephalgic migraine, migrainous disorder, menstrual migraine, abdominal migraine, childhood periodic syndromes, or duster headache.
4. The method of claim 1 or 2, wherein the migraine is episodic migraine, chronic migraine, retinal migraine, ophthalmoplegic migraine, acephalgic migraine, or cluster headache.
5. The method of any one of claims 1-4, wherein the migraine is migraine with aura (classical migraine).
6. The method of any one of claims 1 -4, wherein the migraine is migraine without aura (common migraine).
7. The method of any one of claims 1-6, wherein the migraine is accompanied by allodynia.
8. The method of any one of claims 1-7, comprising administering about 1 mg/kg to about mg/kg, about 10 mg/kg to about 250 mg/kg, about 20 mg/kg to about 150 mg/kg, about 30 mg/kg to about 125 mg/kg, about 40 mg/kg to about 110 mg/kg, about 50 mg/kg to about 100 mg/kg, about 60 mg/kg to about 90 mg/kg, or about 70 mg/kg to about 90 mg/kg, of the compound.
9. The method of any one of claims 1-7, comprising administering about 1 mg/kg, about 2.5 mg/kg, about 5 mg/kg, about 10 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 50 mg/kg, about 75 mg/kg, or about 100 mg/kg of the compound.
10. The method of any one of claims 1-9, comprising administering the compound twice a day, about every day, every 2 days, every 3 days, every 4 days, every 5 days, about once a week, about every two weeks, or about once a month.
11. A method of treating, suppressing, and/or preventing cortical spreading depression in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound represented by:
or pharmaceutically acceptable salt thereof.
or pharmaceutically acceptable salt thereof.
12. A method of treating or ameliorating long-term post migraine sequelae in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound represented by:
or pharmaceutically acceptable salt thereof.
or pharmaceutically acceptable salt thereof.
13. The method of any one of claims 11-12, wherein the compound is administered to the patient with a dose of about 0.01 mg/kg to about 1000 mg/kg or about 1 mg/kg to about 500 mg/kg of the compound.
14. The method of any one of claims 11-12, comprising administering about 1 to about 20 mg/kg, about 2 to about 15 mg/kg; about 5 to about 10 mg/kg, about 10 mg/kg to about 250 mg/kg, about 20 mg/kg to about 150 mg/kg, about 30 mg/kg to about 125 mg/kg, about 40 mg/kg to about 110 mg/kg, about 50 mg/kg to about 100 mg/kg, about 60 mg/kg to about 90 mg/kg, or about 70 mg/kg to about 90 mg/kg, of the compound.
15. The method of any one of claims 11-12, comprising administering about 1mg/kg, about 2.5mg/kg, about 5 mg/kg, about 10 mg/kg, about 21 mg/kg, about 25 mg/kg, about 30 mg/kg, about 50 mg/kg, about 70 mg/kg, or about 10 mg/kg of the compound.
16. The method of any one of claims 11-15, comprising administering the compound twice a day, about every day, every 2 days, every 3 days, every 4 days, every 5 days, about once a week, about every two weeks, or about once a month.
17. The method of any one of claims 1-1 6, further comprising co-administration with an opioid, an antidepressant, an antiepileptic, a non-steroidal anti-inflammatory drug (NSAID), a serotonin 5HT1B/1D agonist, an N-methyl-D-aspartate antagonist, or an anti-inflammatory compound.
18. The method of any one of claims 1-17, wherein the patient is a human.
19. The method of any one of claims 1-18, wherein the patient is female.
20. The method of any one of claims 1-19, wherein the patient is a pediatric or adolescent patient.
21. A method of treating or ameliorating traumatic brain injury in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound represented by:
or pharmaceutically acceptable salt thereof.
or pharmaceutically acceptable salt thereof.
22. The method of claim 21, wherein the compound is administered to the patient with a dose of about 0.01 mg/kg to about 1000 ma/kg or about mg/kg to about 500 mg/kg of the compound.
23. The method of any one of claims 21-22, comprising administering about to about 20 mg/kg, about 2 to about 15 mg/kg; about 5 to about 10 mg/kg, about 10 mg/kg to about 250 mg/kg, about 20 mg/kg to about 150 mg/kg, about 30 mg/kg to about 125 mg/kg, about 40 mg/kg to about 110 mg/kg, about 50 mg/kg to about 100 mg/kg, about 60 mg/kg to about 90 mg/kg, or about 70 mg/kg to about 90 mg/kg, of the compound.
24. The method of any one of claims 21-23, comprising administering the compound twice a day, about every day, every 2 days, every 3 days, every 4 days, every 5 days, about once a week, about every two weeks, or about once a month.
25. The method of any one of claims 21-24, further comprising co-administration with a steroid, antidepressant, an opioid, an antiepileptic, an anti-seizure drug, an anti-convulsant, a non-steroidal anti-inflammatory drug (NSAID), a serotonin 5HT1B/1D agonist, a diuretic, and/or an anti-inflammatory compound.
26. The method of any one of claims 21-25, wherein the patient is a human.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462015727P | 2014-06-23 | 2014-06-23 | |
US62/015,727 | 2014-06-23 | ||
US201562109386P | 2015-01-29 | 2015-01-29 | |
US62/109,386 | 2015-01-29 | ||
PCT/US2015/037177 WO2015200322A1 (en) | 2014-06-23 | 2015-06-23 | Methods of treating or ameliorating migraine |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2953170A1 true CA2953170A1 (en) | 2015-12-30 |
Family
ID=54938737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2953170A Abandoned CA2953170A1 (en) | 2014-06-23 | 2015-06-23 | Methods of treating or ameliorating migraine |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP3157943A4 (en) |
JP (2) | JP6688748B2 (en) |
KR (1) | KR20170018072A (en) |
CN (1) | CN106661085A (en) |
AU (1) | AU2015280108B2 (en) |
BR (1) | BR112016030375A8 (en) |
CA (1) | CA2953170A1 (en) |
MX (1) | MX2016017388A (en) |
RU (1) | RU2721401C2 (en) |
WO (1) | WO2015200322A1 (en) |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995006468A1 (en) * | 1993-09-01 | 1995-03-09 | Smithkline Beecham Corporation | Method for treating migraine headaches |
DE60142806D1 (en) * | 2000-08-25 | 2010-09-23 | Res Corp Technologies Inc | Amino acid-containing anticonvulsants for the treatment of obsessive compulsive disorder |
AU2002227929A1 (en) * | 2000-11-17 | 2002-05-27 | Bayer Aktiengesellschaft | Regulation of human nmda receptor |
MXPA05009425A (en) * | 2003-03-06 | 2006-02-10 | Botulinum Toxin Res Ass Inc | Treatment of sinusitis related chronic facial pain and headache with botulinum toxin. |
KR20110040856A (en) * | 2008-07-23 | 2011-04-20 | 교와 핫꼬 기린 가부시키가이샤 | Therapeutic agent for migraine |
US20120178695A1 (en) * | 2009-07-02 | 2012-07-12 | Joseph Moskal | Methods of treating neuropathic pain |
WO2011044089A2 (en) * | 2009-10-05 | 2011-04-14 | Joseph Moskal | Methods of treating depression and other related diseases |
US8951968B2 (en) * | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
SG10201811584RA (en) * | 2010-02-11 | 2019-01-30 | Univ Northwestern | Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof |
AU2012249397B2 (en) * | 2011-04-27 | 2017-03-30 | Northwestern University | Methods of treating Alzheimer's disease, Huntington's disease, autism, or other disorders |
US20150253305A1 (en) * | 2012-10-12 | 2015-09-10 | Northwestern University | Methods of identifying compounds for treating depression and other related diseases |
-
2015
- 2015-06-23 WO PCT/US2015/037177 patent/WO2015200322A1/en active Application Filing
- 2015-06-23 AU AU2015280108A patent/AU2015280108B2/en not_active Ceased
- 2015-06-23 JP JP2016575106A patent/JP6688748B2/en active Active
- 2015-06-23 KR KR1020177001848A patent/KR20170018072A/en not_active Application Discontinuation
- 2015-06-23 RU RU2017101410A patent/RU2721401C2/en active
- 2015-06-23 MX MX2016017388A patent/MX2016017388A/en unknown
- 2015-06-23 CA CA2953170A patent/CA2953170A1/en not_active Abandoned
- 2015-06-23 CN CN201580033913.6A patent/CN106661085A/en active Pending
- 2015-06-23 BR BR112016030375A patent/BR112016030375A8/en not_active IP Right Cessation
- 2015-06-23 EP EP15811633.5A patent/EP3157943A4/en not_active Withdrawn
-
2020
- 2020-04-06 JP JP2020068289A patent/JP2020114863A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112016030375A8 (en) | 2021-07-13 |
RU2017101410A (en) | 2018-07-24 |
KR20170018072A (en) | 2017-02-15 |
RU2721401C2 (en) | 2020-05-19 |
JP2017519778A (en) | 2017-07-20 |
CN106661085A (en) | 2017-05-10 |
AU2015280108B2 (en) | 2019-11-28 |
AU2015280108A1 (en) | 2017-01-19 |
BR112016030375A2 (en) | 2017-08-15 |
EP3157943A1 (en) | 2017-04-26 |
MX2016017388A (en) | 2018-02-19 |
WO2015200322A1 (en) | 2015-12-30 |
JP6688748B2 (en) | 2020-04-28 |
RU2017101410A3 (en) | 2019-01-21 |
JP2020114863A (en) | 2020-07-30 |
EP3157943A4 (en) | 2018-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2750728T3 (en) | Use of cannabinoids in combination with Aripriprazole | |
ES2791764T3 (en) | Compositions of buprenorphine and mu opioid receptor antagonists | |
US20090163451A1 (en) | Methods for treating visceral pain | |
Yin et al. | Paeoniflorin exerts analgesic and hypnotic effects via adenosine A 1 receptors in a mouse neuropathic pain model | |
US8461389B2 (en) | Psycho-pharmaceuticals | |
US20190298740A1 (en) | Methods and compositions for treating hallucinations and conditions related to the same | |
ES2385138T3 (en) | Rodent disease model for chronic muscle pain | |
US20200046687A1 (en) | Methods and compositions for treating pain | |
US20200129528A1 (en) | Methods for treating blood pressure conditions using aminosterol compositions | |
AU2015280108B2 (en) | Methods of treating or ameliorating migraine | |
ES2362926T3 (en) | NEW COMBINATION OF DRUGS AS AN ANTIDEPRESSIVE. | |
Shanmukha et al. | TPPB modulates PKC activity to attenuate neuroinflammation and ameliorate experimental multiple sclerosis | |
WO2023201247A1 (en) | Methods and compositions for preventing and treating fibrosis and improving functional recovery after injury or with aging | |
JP2012102069A (en) | Treatment agent for early ejaculation | |
JP2011527290A (en) | Application to role in prevention and / or treatment of Alzheimer's disease using potassium 2- (α-hydroxy-pentyl) benzoate | |
Chang | Dopamine D3 regulation of sensorimotor gating | |
NZ785712A (en) | Neuroactive steroids, compositions, and uses thereof | |
Woodall | Actions of two intravenous anaesthetic agents, propofol and ketamine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20200611 |
|
FZDE | Discontinued |
Effective date: 20221115 |
|
FZDE | Discontinued |
Effective date: 20221115 |